MOLECULAR PHARMACOLOGY 44:1279-1288

SUBJECT INDEX FOR VOLUME 44

beta, endocytosis and exocytosis oftransferrin, antimycin A (human), A 364 beta-i and beta-2, regulation by dexamethasone, C8 glioma cells, 1085 beta-2 activation of ion channels, block by physostigmine, BC3H1 cells, amino acid substitutions at position 312, seventh hydrophobic 1051 segment, ill m3 muscarinic , carboxyl-terminal threonine residues, ago- mutant8, desensitization with long-term epinephrine treatment, nist-induced down-regulation (human), 1158 569 rapid perfusion, , channels, 1056 beta-3 Acetylcholinesterase, fetal bovine serum, modulation by monoclonal gene characterization (human), 264 antibody AE-2, carbamate and inhibition, 1152 structural and conformational features, signal transduction, 1094 Acquired immunodeficiency syndrome, HIV-1 reverse transcriptase, Adrenocorticotropic hormone, sequential activation of c-foe, metrazole, selective and synergistic inhibition, MKC-442, 895 adrenal gland (rat), 328 Adenosme Adriamycin, cytochrome P450 2B1-mediated one-electron reduction, antagonist 8-cyclopentyl-1,3-dipropylxanthine, elimination of neu- liver microsomes (rat), 1267 romuscular depression, action of exogenous (frog), 835 w-Agatoxin IVB, structure and properties, antagonist, P-type inhibition of uptake by , specificity, one class of channels (rat), 681 transporters, 1021 Agelenopsis aperta, structure and properties of w-agatoxin IVB, antag- onist, P-type calcium channels (rat), 681 -gated ion channel, inhibition by ethanol (frog), 871 Agonista -induced increases, intracellular calcium levels in PC-12 cells, chronic discrimination from antagonist binding sites, point mutation in 7th ethanol exposure, 405 hydrophobic domain, point mutation in 7th hydrophobic domain, -induced inhibition ofadenylyl cyclase activity, endothelin, C6 glioma 934 cells, 158 dual effects as antagonists, novel neurotensin mimetics, pharmaco- Adenylate cyclase logical studies, 1036 activation, molecular cloning, serotonin receptor (mammal), 229 -induced state of #{244}-opioidreceptor, discrimination, opioid peptides cloned human 5-HT1Da and 5-HTSDP receptors, dual coupling, fibro- and opiate alkaloids, 166 blasts (mouse), 575 Albumin, negatively charged, anti-HIV-1 activity (human), 1003 Adenylyl cyclase Alkaloids, opioid, agonist-induced state, #{244}-opioidreceptor, 166 cAMP and, calcium entry via L-type calcium channels, cardiac Alkanols, cycloa1kanemethanol, volume- and length-dependent loss of myocytes (chicken), 689 activity, Torpedo nicotinic acetylcholine receptor, 1219 coupling of splice variant, somatostatin receptor 2 subtype, 1016 Amioride endothelin- and ATP-induced inhibition, C6 glioma cells, 158 analogues, inhibition of Na-K-Cl cotransport, stimulation of cyclic G protein amino-terminal an/a,, amino acids, regulation ofa, activity, AMP-dependent protein kinase, 393 255 analogues and anti-isehemic properties of inhibitor, pharmacological molecular cloning and functional expression, -opioid receptor, brain characterization, Na/W antiporter isoforms, 1041 (rat), 8 Amines, secretory vesicle biogenic, interaction with plasma membrane, Adrenal gland amphetamine derivatives, 1227 a2-adrenergic receptor 8ubtype distribution (human), 70 Amino acids sequential activation of c-fos, proenkephalin and tyrosine hydroxyl- naturally occurring substitution, functional effects, thymidylate syn- ase, metrazole (rat), 328 these (human), 316 turkey, angiotensin receptors, pharmacological distinction from regulation of a, activity, G protein amino-terminal a,./a. chimeras, mammalian receptors, 1 255 Adrenoceptors substitutions at position 312, seventh hydrophobic segment, fi2- alpha-i adrenergic receptor, 111 comparison of subtypes and signal transduction, neuronal cell transport systems, nitric oxide synthase inhibitors, endothelial cells, lines, 76 615 density and receptor-mediated calcium response, astroglial cells -y-Aminobutyric acid (rat), 247 -induced chloride currenta heterogeneous expression, nephron segments (rat), 926 site agonists, 866 alpha-lA, liver membranes (guinea pig), 589 decay and U-93631, recombinant GABAA receptors (rat), 860 alpha-lB gene induction, cycloheximide, transcription of DDT1 MF- regional sensitivity, t-butylbicyclophosphoro[Sthionate binding, 2 smooth muscle cells, 1105 GABAA receptor subunit (human, rat), 87 alpha-i and a4,ha-2, selective irreversible binding, chloroethylcloni- a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, kainate and, dine, 1165 glutamate receptors, and concanavalin A, 504 alpha-lB and alpha-iD, coupling to multiple signaling pathways, G 5-Amino-4-imidazolecarboxamide riboside, potentiation of metabolism protein and cell type specific, 784 and anti-HJV activity, 2’,3’-dideoxyinosine (human), 30 alpha-2 4-Amino-8-(fl-D-ribofuranosylamino)pyrimido[5,4-d]pyriniidine, inhi- coupling to cyclic AMP-dependent reporter gene, JEG-3 cells, 802 bition of 5-phosphoribosyl-1-pyrophosphate synthetase (human, subtype distribution, multiple tissues (human), 70 mouse), 479

1279 1280 Subject Index

Ammonium, quaternary, blockers, batrachotoxin-modified Na chan- Bleomycin, resistance protein in mammalian cells, nuclear localization, nels, 667 Streptoalloteichus hindustanus, 1135 Amphetamine, derivatives, interaction plasma membrane and secretory Bradykinin vesicle biogenic amine transporters, 1227 cloned receptor, mixed B1 and B2 pharmacological selectivity Ainthamine, activation model for histamine H2 receptor, histamine H2 (mouse), 346 receptor agonists, 886 indirect inhibition of cAMP generation, glomeruli and mesangial Amylin, high affinity binding sites in brain (rat), 493 cells (rat), 818 Analgesia, cannabinoid receptor-binding, structure-activity relation- -induced increases, intracellular calcium levels in PC-12 cells, chronic ships, 1008 ethanol exposure, 405 Anandamide, inhibition of calcium currents, partial agonist, N18 cells, Brain 498 antipeptide antibodies, t-opioid receptors (cattle), 796 Anesthetics cerebral cortex and cerebellum, agonist response kinetics, NMDA isoflurane, positive modulation, human GABAA and recep- receptors (rat),1252 tore, 628 crotical and cerebellar microsacs, inhibition of flux by , benzo- steroids, role of cytochrome P450 in regulation, brain (rat), 1077 diazepine-insensitive GABA chloride channels (rat), 876 Angiotensin, receptor isoform from turkey adrenal gland, pharmaco- cytochrome P450, regulation, anesthetic steroid levels (rat), 1077 logical distinction, mammalian receptors, 1 Dl dopamine receptor expression, identical D1A and D1B receptor Anticancer agents, DNA-binding, antihelicase action, -cyti- mRNAs (opossum), 918 dine intercalator binding, 1064 distribution and modulation, cytochrome P-450 and epoxide hydro- Antiestrogens, inhibition of replication, retroviral Moloney murine laze mRNAs, 990 leukemia virus, 324 high affinity amylin binding sites (rat), 493 , resistance, mutation in Chinese hamster ovary cells, ethyl- membrane, G protein activation, A1 agonists (cattle),115 methanesulfonate exposure, 13 Antimycin A, endocytosis and exocytosis of transferrin, internalization membranes and neuroblastoma cells, BW373U86, G protein-me- and externalization, -adrenergic receptors, 364 diated actions, 827 molecular cloning and functional expression, &-opioid receptor (rat), Anxiety, premenstrual, GABAA receptor regulation, pregnanolone 8 (chick), 191 nonselective-type endothelin, alternative transcript (rat), 533 Aorta, a2-adrenergic receptor subtype distribution (human), 70 opioid receptors, in situ interactions, -binding Arachidonic acid, glutamate and, formation of noradrenalin-induced protein G0 (rat), 62 phosphates, striatal astrocytes, 1176 opioid receptor types and subtypes, differential down- and up-regu- Arrhythmia, delayed rectifier K channel, terfenadine and its metabo- lation, buprenorphine (rat), 173 lites, heart (human), 1240 regulation of nitric oxide synthase, nitric oxide (cattle), 124 Artery, human and bovine, expression of mRNA, 5-HT1D$ receptor striatal astrocytes, formation of noradrenalin-induced inositol phos- subtype, 242 phates, arachidonic acid and glutamate, 1176 Aryl hydrocarbon, receptor nuclear translocator protein, dioxin recep- 1-(4-Bromo-2,5-dimethocyphenyl)-2-aminopropane, 5-HT1 receptor tor action, 511 density and mRNA levels, choroid plexus epitheial cells (rat), 725 Aspartate, mutation at residue 89, somatostatin receptor subtype 2, a--sensitive acetylcholine receptors, retina (chick), 1046 Na regulation (mouse), 380 Buprenorphine, differential down- and up-regulation, opioid receptor Astrocytes, striate.!, formation of noradrenalin-induced inositol phos- types and subtypes (rat), 173 phates, arachidonic acid and glutamate, 1176 t-Butylbicyclophosphoro[S]thionate, binding and GABAA receptor a Astroglial cells, receptor-mediated calcium response, quantitative re- subunit, regional ‘y-aminobutyric acid sensitivity (human, rat), 87 lationship, a1-adrenergic receptor density, 247 BW373U86, G protein-mediated actions, brain membranes, neuro- Azidopamil, a binding site, 966 blastoma cells, 827

B C

B29,B29’-suberoyl-insulin, heterogeneity of insulin receptors, tissues Cadmium, cisplatin resistance and, mouse metaflothionein, cell survival (rat), 271 in CHO cells, 44 Baculovirus, -Sf-21 insect cell system, pharmacological characteriza- Calcium tion, cloned human NK-2 neurokinin A receptor, 356 cAMP levels and, P2u purinergic receptors, protein kinase C and , role of fi subunit, pharmacology, GABAA receptors (hu- glioma cells (rat), 1185 man), 1211 -dependent and -independent protein kinase isozymes, and Barium, blockade of clonal potassium channel, regulation, critical pore substrate specificity (insect), 298 residue, 180 dual coupling in fibroblasts, cloned human 5HTlDa and 5-HTSDe Batrachotoxin-modified Na channels, quaternary ammonium block- receptors (mouse), 575 era, 667 enkephalin gene transcription, DNase I-hypersensitive sites, chro- BC3H1 cells, physostigmine block of ion channels, acetylcholine, 1051 maffm cells (cattle), 545 Benzodiazepine entry via L-type calcium channels, adenylyl cyclase and cAMP, GABAA receptors cardiac myocytes (chicken), 689 regulation, pregnanolone (chick), 191 intracellular, 2,3,7,8-tetrachlorodibenzo-p-dioxin, ventricular con- role of ‘y subunits (human), 437 tractile responses (chick), 1142 -insensitive GABA chloride channels, inhibition of flux by zinc, intracellular levels in PC-12 “ells, ATP- and bradykinin-mduced cortical and cerebellar microsacs (rat), 876 increases, chronic ethanol exposure, 405 role of 9 subunit, pharmacology, GABAA receptors (human), 1211 mobilization induced by inositol-1,3,4,5-tetrakisphosphate, receptor, site agonists, GABA-induced chloride currents, 866 SH-SY5Y neuroblastoma cells, 810 Benzoquinoid, tyrosine kinase inhibitors, blockers of cardiac musca- receptor-mediated response, a,-adrenergic receptor density, quanti- rinic receptor function (bullfrog), 595 tative relationship (rat), 247 Subjectindex 1281

red cell transport, irreversible modification, phenylglyoxal, 399 a-, phospholipase A2 activity, thytnopoietin preparations, release channel, activating and deactivating effects, natural ryano- 678 dine congeners (rabbit), 412 Colon, a2-adrenergic receptor subtype distribution (human), 70 responses mediated by signal transduction, endothelin receptors, Colonic neoplasms, cytotoxicity of 5-fluorouracil/interferon-a-2a, N- follicular membranes of Xenopue oocytes, 153 (phosphonacetyl)-L-aspartate (human), 1070 role of G1 and, endothelin- and ATP-induced inhibition, adenylyl Concanavalin A, cyclothiazide and, a-amino-3-hydroxy-5-methyl-4- cyclase activity in C6 cells, 158 isoxazolepropionic acid and karnate-preferring glutamate recep- Calcium channels tors, 504 modulation of NMDA receptor channel function, nitrendipine, neu- -treated vitamin E- and selenium-deficient rats, electron spin rons (mouse), 443 resonance, free radical generation, 222 P-type, w-agatoxin IVB, structure and properties (rat), 681 COS-7 cells, estrogenic activity, commonly occurring plant flavonoids, voltage-sensitive, pharmacological characterization, w-grammotoxin 37 SIA, 451 , interaction with nicotinic acetylcholine receptor, selective en- Calcium currents hancement (mouse), 237 inhibition by anandamide, partial agonist, N18 cells, 498 Cyclic AMP inhibition by 3-isobutyl-1-methylxanthine, cAMP, neuronal and en- adenylyl cyclase and, calcium entry via L-type calcium channels, docrine cells, 622 cardiac myocyt.es (chicken), 689 Cannabinoid cytosolic Ca2 and, P2u purinergic receptors, protein kinase C and anandamide, inhibition of calcium currents, partial agonist in N18 glioma cells (rat), 1185 cells, 498 -dependent protein kinase receptor-binding and analgesic activity, structure-activity relation- enhancement, GABA type A receptor currents, 1202 ships, 1008 inhibition of Na-K-Cl cotransport, amioride analogues, 393 Carbamate, modulation by monoclonal antibody AE-2, fetal bovine -dependent reporter gene, coupling of a2-adrenergic receptor sub- serum acetylcholinesterase, 1152 types, JEG-3 cells, 802 elevation in PC12 cells, multiple mechanisms, desensitization of A2a Carbonic anhydrase IV, chemical properties, 901 adenosine receptor, 950 Catecholamines functional role of M2 muscarinic receptor, smooth muscle, ileum ligand binding and functional studies, a-like receptor, phenylami- (guinea pig), 102 notetralins, 1232 indirect inhibition of generation by bradykinin, glomeruli and mes- regulation of beta adrenoceptors, dexamethasone, C6 glioma cells, angial cells (rat), 818 1085 inhibition of adenosine uptake by ethanol, specificity, one clam of 293 cells, transfected, paradoxical regulation, dopamine receptors, 371 nucleoside transporters, 1021 Central nervous system, Xenopus, reconstitution of inhibition of sustained calcium current, 3-isobutyl-1-methylxan- proteins, artificial bilayers, 142 thine, neuronal and endocrine cells, 622 Cerebellum molecular cloning and functional expression, -opioid receptor, brain granule cells (rat), 8 agonist-induced down-regulation, m2- and m-muscarmnic acetyl- Cyclic GMP-elevating agents, inhibition of phospho- receptor, 940 diesterase isoforms, thymocyt.e proliferative response, 1027 developmental changes, metabotropic glutamate receptors, 981 Cycloalkanemethanols, volume- and length-dependent loss of activity, regulation of nitric oxide synthase, nitric oxide (cattle), 124 alkanols, Torpedo nicotinic acetylcholine receptor, 1219 aj/a,, amino acids, regulation of Chimera, G protein amino-terminal Cycloheximide, induction ofalpha-1B adrenoceptor gene, transcription, a, activity, 255 DDT1 MF-2 smooth muscle cells, 1105 Chinese hamster ovary cells 8-Cyclopentyl-1,3-dipropylxanthine, elimination of neuromuscular cell survival, cisplatin and cadmium resistance, mouse metallothi- depression, action of exogenous adenosine (frog), 835 44 onein, Cyclosporin A, immunosuppressive activity, lysophospholipid-me- mutations leading to antifolate resistance, ethylmethanesulfonate diated inhibition, Na,K-ATPase, 605 exposure, 13 Cyclothiazide, concanavalin A and, a-amino-3-hydroxy-5-methyl-4- Chloride channels, benzodiazepine-irisensitive, inhibition of flux by isoxazolepropionic acid and kainate-preferring glutamate recep- zinc, cortical and cerebellar microsacs (rat), 876 tors, 504 Chloride currents CYPJAI, negative regulatory element, interaction with protein, liver GABA-induced and hepatoma cells, 560 benzodiazepine site agonists, 866 Cytidine-guanosine intercalator binding, antihelicase action, DNA- decay and U-93631, recombinant GABAA receptors (rat), 860 binding anticancer agents, 1064 Chlorocresol, activator, ryanodine receptor-mediated Ca2 release, 1192 Cytochrome P-450 Chloroethylclonidine, selective irreversible binding, alpha-i and -2 block of gene transcription, RU486 (rat), 775 adrenoceptor subtypes, 1165 cytokine down-regulation of major , adult hepatocytes in (2-Chloroethyl)-3-sarcosinamide-1-nitrosourea, transport in human primary culture (human), 707 glioma cell line SK-MG-i, mediation, epinephrine-sensitive carrier liver microsomal, reductive metabolism, zonisamide (human), 216 system, 204 regional distribution and expression modulation, epoxide hydrolase Choroid plexus, epithelial cells, 5-HT1c receptor density, mRNA levels mRNA, brain (rat), 990 (rat), 725 regulation, level of anesthetic steroids, brain (rat), 1077 Chromaffin cells, enkephalin gene transcription, DNase 1-hypersensi- Cytochrome P-450 2B1-mediated one-electron reduction, Adriamycin, tive sites (cattle), 545 liver microsomes (rat), 1267 Cisplatin, cadmium resistance and, mouse metallothionein, cell survival Cytochrome P-450 2C7, induction of mRNA, growth hormone and in CHO cells, 44 vitamin A, primary hepatocytes (rat), 997 Clara cells, differentiation, postnatal changes in expression and distri- Cytochrome P-450 monooxygenases, pulmonary, postnatal changes in bution, pulmonary cytochrome P450 monooxygenases (rabbit), 51 expression and distribution, Clara cell differentiation (rabbit), 51 1282 Subject Index

Cytokines, down-regulation of major cytochrome P-450 enzymes, adult nonselective-type receptor, alternative transcript, brain (rat), 533 hepatocytes in primary culture (human), 707 receptors in follicular membranes, calcium responses, Xenopu.s oo- Cytosol, Ca2 and cAMP levels, P2 purinergic receptors, protein kinase cytes, 153 C and glioma cells (rat), 1185 receptor subtypes, expression, saphenous vein (rabbit), 959 type A receptors, MMQ cells, 285 D Enkephalin, gene transcription, DNase I-hypersensitive sites, chro- DAGO, molecular cloning and functional expression, -opioid receptor, maffin cells (cattle), 545 brain (rat), 8 Enzymes, membrane-bound, chemical properties, carbonic anhydrase 4-DAMP mustard, functional role of M2 muscarinic receptor, smooth Iv, 901 muscle, ileum (guinea pig), 102 Epinephrine a-Dendrotoxin, binding site interaction with tityustoxin-Ka, cloned long-term treatment and desensitization, beta-2 adrenoceptor mu- Kvl.2 K channel, 430 tants, 569 2 ‘ -, phosphorylation of enantiomers of carbocyclic an- -sensitive carrier system, transport of (2-chloroethyl)-3-sarcosinam- alog, HSV-1 and uninfected cells, 1258 ide-1-nitrosourea, human glioma cell line SK-MG-1, 204 Dexamethasone, regulation of beta adrenoceptors, C6 glioma cells, 1085 Epithelial cells, choroid plexus, 5-HT1 receptor, density and mRNA 2’,3’-Dideoxycytidine, anti-HIV-1 therapy, peripheral neuropathy, levels (rat), 725 PC12 cells, 702 Epitopes, allosteric interactions, use of chimeric muscarinic receptors, 2’,3’-Dideoxyinosine, potentiation of anti-HIV activity, 5-amino-4- 583 imidazolecarboxamide riboside (human), 30 Epoxide hydrolase, mRNA in brain, distribution and modulation, cy- Dihydrofolate reductase tochrome P-450 (rat), 990 alteration of pre-mRNA splicing, 5-fluorouracil, quantitative PCR Estrogen, estrogenic activity, commonly occurring plant flavonoids, (human), 22 HeLa and COS-7 cells, 37 mutations leading to antifolate resistance, ethylmethanesulfonate Ethanol exposure, CHO cells, 13 chronic exposure, ATP- and bradykinin-induced increases, intracel- Dihydropyridine, nitrendipine, modulation of NMDA receptor channel lular calcium levels in PC-12 cells, 405 function, (mouse), 443 inhibition, neuronal ATP-gated ion channel (frog), 871 1,25-Dihydroxyvitamin D3, transcription and expression, inositol tris- inhibition of adenosine uptake, specificity, one class of nucleoside phosphate gene, HL-60 cells, 292 transporters, 1021 Dioxin, aryl hydrocarbon receptor nuclear translocator protein, 511 #{244}-opioidreceptor gene expression, neuronal cell lines, 1119 Disulfiram, peptide a-amidation, peptidylglycine cr-hydroxylating mon- Ethylmethanesulfonate, exposure of Chinese hamster ovary cells, mu- ooxygenase, 972 tations leading to antifolate resistance, 13 DNA-binding anticancer agents, antihelicase action, guanosine-cyti- F dine intercalator binding, 1064 DNA, complementary Fat, a2-adrenergic receptor subtype distribution (human), 70 fl3-adrenergic receptor gene characterization (human), 264 Fibroblasts human Ah receptor, cloning and expression, 911 dual coupling, cloned human 5-HTlD and 5-HT1DP receptors DNase I-hypersensitive sites, enkephalin gene transcription, chromeS- (mouse), 575 fin cells (cattle), 545 Swiss 3T3, modulation of number of endothelin receptors, phosphor- DNA topoisomerases, I and II inhibition by introplicine, early clinical amidon, 422 trials, 767 FK888, pulmonary neurokinin type 1 receptors, characterization Dopamine (guinea pig), 539 identical receptor mRNAs, cloning and characterization, kidney and Flavonoids, plant, estrogenic activity, HeLa and COS-7 cells, 37 brain (opossum), 918 2’--Fluoro-2’,3’-dideoxynucleosides, anti-HIV activity, enhanced modulation of novel subtype, sulfonylurea-sensitive potassium chan- stimulation by ribavirin, 5’-phosphorylation, 519 nels (rat), 907 5-Fluorouracil Drosophila, nervous system, muscarmnic acetylcholine receptor, immu- alteration of dihydrofolate reductase pre-mRNA splicing, quantita- nocytochemistry, 716 tive PCR (human), 22 DT-diaphorase -interferon-a-2a, cytotoxicity in colon cancer cell lines, N-(phos- pH-dependent inactivation, mitomycin C and porfiromycin, 1128 phonacetyl)-L-aspartate (human), 1070 role of NAD(P)H:(quinone acceptor) oxidoreductase, activation of Free radicals, generation, electron spin resonance, copper-treated vi- mitomycin C, acidic conditions, 210 tamin E- and selenium-deficient rats, 222 fi-Funaltrexamine-labeled -opioid receptors, species variations, com- E plex-type N-olinked oligosaccharides (guinea pig, rat, mouse), 749 Electron spin resonance, free radical generation, copper-treated vita- G mm E- and selenium-deficient rats, 222 Emopamil, a binding site, 966 Galactose, drug targeting, lipoprotein-like lipid particles (human), 486 Endocrine cells, inhibition of sustained calcium current, 3-isobutyl-1- Gallamine, epitopes in allosteric interactions, use of chimeric musca- methylxanthine, 622 rinic receptors, 583 Endoplasmic reticulum, postnatal changes in expression and distribu- Gap junction, calcium responses mediated by signal transduction, en- tion, pulmonary cytochrome P450 monooxygenases, Clara cell dothelin receptors, follicular membranes of Xenopus oocytes, 153 differentiation (rabbit), 51 Gene Endothelial cells, amino acid transport, actions of nitric oxide synthase $3-adrenergic receptor (human), 264 inhibitors (pig), 615 cAMP-dependent reporter, coupling of a2-adrenergic receptor sub- Endothelin types, JEG-3 cells, 802 ATP-induced inhibition of adenylyl cyclase activity, role of G and c-fos, induction of sequential activation, metrazole (rat), 328 calcium, C6 glioma cells, 158 cytochrome P-450, block of transcription, RU486 (rat), 775 modulation of receptor number, phosphoramidon, Swiss 3T3 fibro- enkephalin, transcription in chromaffin cells, DNase 1-hypersensi- blasts, 422 tive sites (cattle), 545 Subjectlndex 1283

inositol trisphosphate, expression and transcription, 1,25-dihydroxy- delayed rectifier K channel, terfenadine and its metabolites (hu- vitamin D3, 292 man), 1240 mouse metaflothionein, cisplatin and cadmium resistance, cell sur- muscarinic receptor function, blockers, benzoquinoid tyrosine kinase vival in CHO cells, 44 inhibitors (bullfrog), 595 Glioma myocytes, calcium entry via L-type calcium channels, adenylyl cy- C6 cells, regulation of beta adrenoceptors, dexamethasone, 1085 clase and cAMP (chicken), 689 endothelin- and ATP-induced inhibition, adenylyl cyclase activity, HeLa cells, estrogenic activity, commonly occurring plant flavonoids, 158 37 P2U purinergic receptors on glioma cells, cytosolic Ca2 and cAMP Helicase, antihelicase action, DNA-binding anticancer agents, guano- levels, protein kinase C (rat), 1185 sine-cytidine intercalator binding, 1064 transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea, media- Hepatocytes tion, epinephrine-sensitive carrier system, 204 induction of P4502C7 mRNA, growth hormone, vitamin A (rat), 997 Glomeruli, indirect inhibition of cAMP generation, bradykinin (rat), primary culture, cytokine down-regulation, major cytochrome P-450 818 enzymes (human), 707 Glucocorticoid, sequential activation of c-foe, metrazole, adrenal gland Hepatoma, CYPJAJ negative regulatory element, interaction with pro- (rat), 328 tein, 560 Glutamate Herpes simplex virus, type 1, phosphorylation of enantiomers, carbo- arachidonic acid and, formation of noradrenalin-induced inositol cyclic analog of 2’-deoxyguanosine, 1258 phosphates, striatal astrocytes, 1176 Hippocampus, live CAl neurons, diversity of expression, glutamate receptor protein reconstitution, artificial bilayers, Xenopus central receptor subunit mRNA expression (rat), 308 nervous system, 142 Histamine, H2 receptor agonists, activation model, histamine H2 recep- receptor subunit mRNA expression, diversity, hippocampal CAl tor, 886 neurons (rat), 308 Histidine, naturally occurring amino acid substitution, functional ef- Glycine, inhibitory receptor, extracellular disulfide loop motif, 198 fects, thymidylate synthase (human), 316 G proteins HIV-l activation by A1 adenosine receptor agonists, brain membranes (cat- anti-HIV-1 therapy, peripheral neuropathy, PC12 cells, 702 tle), 115 drug-resistance patterns, 1-[(2-hydroxyethoxy)methylj-6-(phenyl- amino-terminal az/a. chimeras, amino acids, regulation of a, activ- thio) derivatives, 694 ity, 255 reverse transcriptase, selective and synergistic inhibition, MKC-442, aspartate mutation at residue 89, somatostatin receptor subtype 2, 895 Na regulation of agonist binding (mouse), 380 HL-60 cells, inositol trisphosphate gene, expression and transcription, cloned somatostatin receptors SSTR4 and SSTR5 (human), 385 292 -coupled functions, modification by low-pH pretreatment of mem- Human immunodeficiency virus branes, NG1O8-15 cells, 731 anti-virus activity ofpurine 2’--fluoro-2’,3’-dideoxynucleosides, en- coupling of a1- and alD-adrenergic receptors, multiple signaling hanced simulation by ribavirin, 5’-phosphorylation, 519 pathways, 784 potentiation of anti-HIV activity, 5-amino-4-imidazolecarboxamide dual coupling in fibroblasts, cloned human 5-HT1 and 5-HT1D$ riboside, 2’,3’-dideoxyinosine (human), 30 receptors (mouse), 575 Human immunodeficiency virus-i, anti-HIV-1 activity, negatively in situ interactions with G0, brain opioid receptors (rat), 62 charge serum albumins (human), 1003 -mediated actions, BW373U86, brain membranes and neuroblastoma Hydrocarbons, polycycic aromatic, interactions with indolo[3,2-bjcar- cells, 827 bazoles, 2,3,7,8-tetrachlorodibenzo-p-dioxin binding, liver (rat), role of G and calcium, endothelin- and ATP-induced inhibition, 336 adenylyl cyclase activity in C6 cells, 158 i-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine, derivatives, w-Grammotoxin, SIA, pharmacological characterization, voltage-sen. HIV-1 drug-resistance patterns, 694 sitive calcium channel rseponses, 451 Granule cells I cerebellar Ifenprodil, discrimination of subtypes, NMDA receptor, heteromeric agonist-induced down-regulation, m2- and m3-muscarinic acetyl- receptors (rat), 851 choline receptor, 940 Ileum developmental changes, metabotropic glutamate receptors, 981 a2-adrenergic receptor subtype distribution (human), 70 Growth hormone, vitamin A and, induction of P4502C7 mRNA, pri- functional role, M2 muscarinic receptor (guinea pig), 102 mary hepatocytes (rat), 997 Immunocytochemistry, Drosophila nervous system, muacarinic acetyl- Guanosine-cytidine intercalator binding, antihelicase action, DNA- choline receptor, 716 binding anticancer agents, 1064 Immunosuppression, cyclosporin A, lysophospholipid-mediated inhi- Guanosine-5’-O-(3-[S]thio)triphosphate, binding, G protein activa- bition, Na,K-ATPase, 605 tion in brain membranes, A1 adenosine receptor agonists (cattle), Indole analogs, molecular mechanism of 6-selectivity, nonpeptide 115 opioids, 1246 Guanylate cyclase, regulation of nitric oxide synthase, nitric oxide Indolo[3,2-bjcarbazoles, interactions with related polycyclic aromatic (cattle),124 hydrocarbons, 2,3,7,8-tetrachlorodibenzo-p-dioxin binding, liver (rat), 336 H Inositol-i,3,4,5-tetrakisphosphate, induction of calcium mobilization Heart via receptor, SH-SY5Y neuroblastoma cells, 810 a2-adrenergic receptor subtype distribution (human), 70 Inositol phosphates, noradrenalin-induced, role of arachidonic acid and angiotensin II receptor expression, Xenopus laeuis, 277 glutamate, striatal astrocytes, 1176 block of rapidly activating delayed rectifier K channel, verapamil, Inositol trisphosphate, gene expression and transcription, 1,25-dihy- 642 droxyvitamin D3, HL-60 cells, 292 1284 Subject Index

Insulin, heterogeneity of receptors, tissues, B29,B29’-suberoyl-insulin Lysophospholipid-mediated inhibition, Na,K-ATPaae, immunosup- (rat), 271 pressive activity, cyclosporin A, 605 Interferon-a-2a/5-fluorouracil, cytotoxicity in colon cancer cell lines, M N-(phosphonacetyl)-L-aspartate (human), 1070 Introplicine, dual toposiomerase I and H inhibition, early clinical trials, Macrophages, poly(Ai RNA, pore-forming P purinoceptor, Xenopus 767 oocytes, 93 Ion channel Mammalian cells, bleomycin resistance protein, nuclear localization, ATP-gated, inhibition by ethanol (frog), 871 Streptoalloteichus hindu,stanus, 1135 inhibitory glycine receptor, extracellular disulfide loop motif, 198 Mesangial cells, indirect inhibition of cAMP generation, bradykinin physostigmine block, activation by acetylcholine, BC3H1 cells, 1051 (rat), 818 Ischemia, inhibitor exhibiting anti-ischemic properties, pharmacologi- Metallothionein, mouse, cisplatin and cadmium resistance, cell survival cal characterization, Na’7H4 antiporter isoforms, 1041 in CHO cells, 44 3-Isobutyl-1-methylxanthine, inhibition of sustained calcium current, , mutations leading to antifolate resistance, ethylmetha- cAMP, neuronal and endocrine cells, 622 nesulfonate exposure, CHO cells, 13 Isoflurane Methylurapidil, alpha-lA adrenoceptors, liver membranes (guinea pig), acetylcholine receptor channels, rapid perfusion of acetylcholine, 589 1056 Metrazole, induction of sequential activation, c-fos/proenkephalin/ positive modulation, human GABAA and glycine receptors, 628 tyrosine hydroxylase gene expression, adrenal gland (rat), 328 Isoproterenol, 2,3,7,8-tetrachlorodibenzo-p-dioxin, cardiac myocyte in- Mianserin, 5-HT, receptor density and mRNA levels, choroid plexus tracellular calcium, ventricular contractile responses (chick), 1142 epithelial cells (rat), 725 Microtubules, inhibition of assembly, spongistatin 1, binding of yin- J blastine to tubulin (sponge), 757 JEG-3 cells, coupling of a2-adrenergic receptor subtypes, cAMP-de- Migraine, expression of mRNA, 5-HTlD receptor, human and bovine arteries, 242 pendent reporter gene, 802 Jejunum, a2-adrenergic receptor subtype distribution (human), 70 Mitomycin C pH-dependent inactivation, DT-diaphorase, 1128 K role of NAD(P)H:(quinone acceptor) oxidoreductase, activation un- der acidic conditions, 210 Kainate, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and, Mitosis, inhibition by spongistatin 1, binding of vinblastine to tubulin glutamate receptors, cyclothiazide and concanavalin A, 504 (sponge), 757 Kidney MKC-442, selective and synergistic inhibition, HIV-l reverse transcrip- a2-adrenergic receptor subtype distribution (human), 70 tase, 895 Dl dopamine receptor expression, identical D1A and D1B receptor MMQ cells, type A endothelin receptors, 285 mRNAs (opossum), 918 Monoclonal antibodies, AE-2, modulation of carbamate and organo- phosphate inhibition, fetal bovine serum acetylcholinesterase, 1152 L Multidrug resistance, reversal of Vinca alkaloid resistance, N-substi- Leukemia virus, Moloney murine, inhibition of replication, antiestro- tuted phenoxazines, 552 gens, 324 Muscle Ligands DDT, MF-2 cells, alpha-lB gene induction, cycloheximide, 1105 binding sites elimination of neuromuscular depreesion, action of exogenous aden- neuronal nicotinic acetylcholine receptors, chimeric a subunits, osine, 8-cyclopentyl-1,3-dipropylxanthine (frog), 835 657 skeletal, a2-adrenergic receptor subtype distribution (human), 70 role of threonine 342 in helix 7, 5-HTID receptor, 882 Muscle, skeletal, high affinity amylin binding sites, brain (rat), 493 binding specificity, amino acid substitutions at position 312, 2 Muscle, smooth, ileum, functional role, M2 muscarinic receptor (guinea adrenergic receptor, 111 pig), 102 inhibitory glycine receptor, extracellular disulfide loop motif, 198 Mutagenesis, selective enhancement, interaction of curare, nicotinic substrate specificity and, calcium, protein kinase isozymes (insect), acetylcholine receptor (mouse), 237 298 Myocytes Lipid, lipoprotein-like particles, drug targeting (human), 486 cardiac, calcium entry via L-type calcium channels, adenylyl cyclase Lipoprotein-like lipid particles, drug targeting (human), 486 and cAMP (chicken), 689 Liver intracellular calcium, 2,3,7,8-tetrachlorodibenzo-p-dioxin, isoproter- a2-adrenergic receptor subtype distribution (human), 70 enol (chick), 1142 CYP1AJ negative regulatory element, interaction with protein, 560 N drug targeting, lipoprotein-like lipid particles (human), 486 2,3,7,8-tetrachlorodibenzo-p-dioxin binding, interactions, indolo[3,2- Na,K-ATPase, lysophospholipid-mediated inhibition, immunosup- bjcarbazoles and related polycyclic aromatic hydrocarbons (rat), pressive activity, cyclosporin A, 605 336 NAD(P)H:(quinone acceptor) oxidoreductase, role in activation of mi- Liver, membranes, alpha-lA adrenoceptors (guinea pig), 589 tomycin C, acidic conditions, 210 Liver microsomes Na/H antiporter, pharmacological characterization, amiloride ana- cytochrome P450, reductive metabolism, zonisamide (human), 216 logs, inhibitor with anti-ischemic properties, 1041 cytochrome P450 2B1-mediated one-electron reduction, Adriamycin Na/K-ATPase, interaction of tricyclic drug analogs, synaptic plasma (rat), 1267 membranes (rat), 129 Lung NB41A3 cells, comparison of a,-adrenergic receptor subtypes, signal a2-adrenergic receptor subtype distribution (human), 70 transduction, 76 cytochrome P450 monooxygenases, postnatal changes in expression Nephron, segments, heterogeneous expression, a,-adrenoceptor sub- and distribution, Clara cell differentiation (rabbit), 51 types (rat), 926 neurokinin type 1 receptors, [3H]FK888, characterization (guinea Nervous system, Drosophila, muscarinic acetylcholine receptor, im- pig), 539 munocytochemistry, 716 Subjectlndex 1285

Neuroblastoma derived from purified i-opioid binding protein, antisera, brain regions brain membranes and, BW373U86, G protein-mediated actions, 827 and cell line (cattle), 796 partial agonist, anandamide, inhibition of calcium currents, 498 opioid, agonist-induced state, #{244}-opioidreceptor, 166 SK-N-SH cells, interactive down-regulation, ,i- and #{244}-opioidrecep- Peptidyiglycine a-hydroxylating monooxygenase, peptide a-amidation tore, 461 and, control by disulfiram, 972 Neurokinin A, NK-2 receptor, pharmacological characterization, bac- Pertussis toxin, dual coupling in fibroblasta, cloned human 5-HT1D,. ulovirus/Sf-21 insect cell system, 356 and 5-HT1D, receptors (mouse), 575 Neuromedin B, receptor antagonists, substituted somatostatin ana- pH logues (rat), 841 -dependent inactivation, DT-diaphorase, mitomycin C and porfiro- Neuronal cells mycin, 1128 comparison of a1-adrenergic receptor subtypes, signal transduction, low, modification of G protein-coupled functions, NG1OS-15 cells, 76 731 inhibition of sustained calcium current, 3-isobutyl-l-methylxan- Phenobarbital-induced transcriptional activation, cytochrome P-450 thine, 622 genes, block by RU486 (rat), 775 Neurons Phenoxazines, N-substituted, reversal of Vinca alkaloid resistance, agonist response kinetics, NMDA receptors (rat), 1252 multidrug-resistant cancer cells, 552 cell line, #{244}-opioidreceptor gene expression, ethanol, 1119 Phenylalkylamine-binding polypeptide, a binding site, photoaffinity hippocampal CAl, diversity, glutamate receptor mRNA expression labeling and ligand-directed antibodies, 966 (rat), 308 Phenylaminotetralins, r-like receptor, ligand binding, functional stud- modulation of NMDA receptor channel function, nitrendipine ies, 1232 (mouse), 443 Phenylglyoxal, irreversible modification, red cell Ca2 transport, 399 pharmacological characterization, w-grammotoxin SIA, voltage-sen- Phosphodiesterase, cyclic nucleotide isoforms, thymocyte proliferative sitive calcium channel responses, 451 response, cGMP-elevating agents, 1027 Neuropathy, peripheral, anti-HIV-1 therapy, PC12 cells, 702 Phosphoinositide, functional role of M2 muscarinic receptor, smooth Neurotensin, mimetics, pharmacological studies, dual effects as antag- muscle, ileum (guinea pig), 102 onist and agonist, 1036 Phospholipase A2, a-cobratoxin and, thymopoietin preparations, 678 Neurotranamitter, reconstitution of glutamate receptor proteins, arti- N-(Phosphonacetyl)-L-aspartate, cytotoxicity of 5-fluorouracil/inter- ficial biayers, Xenopus CNS, 142 feron-a-2a, colon cancer cell lines (human), 1070 NG1O8-15 cells Phosphoramidon, modulation of number of endothelin receptors, Swim inhibition of potassium current, transfected D2 short dopamine re- 3T3 fibroblasts, 422 ceptors, 649 5-Phosphoribosyl-1-pyrophosphate synthetase, inhibition by 4-amino- modification of G protein-coupled functions, low-pH pretreament of 8-($-D-ribofuranosylamino)pyrimido[5,4-djpyrimidine (human, membranes, 731 mouse), 479 Nitrendipine, modulation of NMDA receptor channel function, neu- Photoaffinity, labeling and ligand-directed antibodies, 27-kDa high rons (mouse), 443 affinity phenylalkylamine-binding polypeptide, 966 Nitric oxide synthase Physostigmine, block of ion channels, activation by acetylcholine, inhibitors, endotheial cell amino acid transport systems, 615 BC3H1 cells, 1051 regulation by nitric oxide (cattle), 124 Plasma membrane Noradrenalin-induced inositol phosphates, role ofarachidonic acid and secretory vesicle biogenic amine transporters, interactions, amphet- 1176 glutamate, striatal astrocytes, amine derivatives, 1227 Nucleoside, transporters, inhibition of adenosine uptake, ethanol, 1021 synaptic, interaction, tricyclic drug analogs (rat), 129 Poly(A), RNA from murine macrophages, pore-forming P purino- 0 ceptor, Xenopus oocytes, 93 Oligosaccharides, complex-type N-linked, -funaltrexamine-labeled - Polytnerase chain reaction, quantitative, 5-fluorouracil, altered dihy- opioid receptors, species differences (guinea pig, rat, mouse), 749 drofolate reductase pre-mRNA splicing (human), 22 Oocytes, Xenopus, pore-forming Pz purinoceptor, poly(Ai RNA from Polypeptides, 27-kDa high affinity phenylalkyla.mine-binding, a bind- murine macrophages, 93 ing site, 966 Opiates, alkaloids, agonist-induced state of #{244}-opioidreceptor, 166 Pore, critical residue, barium blockade, clonal potassium channel, 180 Opioids Porfiromycin, pH-dependent inactivation, DT-diaphorase, 1128 agonist efficacy, G-protein-coupled functions, NG1O8-15 cells, 731 Potassium channel mu, antisera against peptides, brain regions and cell line (cattle), 796 clonal, barium blockade, regulation of critical pore residue, 180 nonpeptide, molecular mechanism of &-selectivity, indole analogs, cloned Kvl.2, a-dendrotoxin binding site interaction, tityustoxin- 1246 Ka, 430 Organophosphate, inhibition of fetal bovine serum acetylcholinester- delayed rectifier, terfenadine and its metabolites, heart (human), ase, modulation by monoclonal antibody AE-2, carbamate, 1152 1240 rapidly activating delayed rectifier, block by verapamil, cloned from P human heart, 642 Pancreas, a2-adrenergic receptor subtype distribution (human), 70 sulfonylurea-sensitive, novel subtype, modulation by dopamine (rat), PC12 cells 907 anti-HIV-l therapy, peripheral neuropathy, 702 Potassium current, inhibition, transfected D2 short dopamine receptors, cyclic AMP elevation, multiple mechanisms, desensitization of A2a NG1O8-15 cells, 649 adenosine receptor, 950 Pregnanolone, GABAA receptor regulation (chick), 191 intracellular calcium levels, ATP- and bradykinin-induced increases, Proenkephalin, induction of sequential activation, metrazole, adrenal chronic ethanol exposure, 405 gland (rat), 328 Peptides Prostate, a2-adrenergic receptor subtype distribution (human), 70 a-amidation and peptidylglycine a-hydroxylating monooxygenase, Protein, CYPJAJ negative regulatory element, liver and hepatoma cells, control by disulfiram, 972 560 1286 Subject Index

Protein kinase diversity of mRNA expression, live hippocampal CAl neurons calcium-dependent and -independent isozymes, ligand and substrate (rat), 308 specificity (insect), 298 diversity of subunit mRNA expression, live hippocampal CAl cAMP-dependent neurons (rat), 308 enhancement, GABAA receptor currents, 1202 reconstitution of proteins into artificial biayers, Xenopus CNS, inhibition of Na-K-Cl cotransport, amiloride analogues, 393 142 Protein kinase A, enkephalin gene transcription, DNase 1-hypersensi- glycine, extracellular disulfide loop motif, 198 tive sites, chromaffin cells (cattle), 545 histamine H2, activation model, 886 Protein kinase C, indirect inhibition of cAMP generation, bradykinin, 5-HT1, density and mRNA levels, choroid plexus epithelial cells glomeruli and mesangial cells (rat), 818 (rat), 725 , 2’ 9’ -dideoxynucleosides, enhanced stimulation by 5-HTID, role of threonine 342 in helix 7, ligand binding, 882 ribavirin, 5’-phosphorylation and anti-HP? activity, 519 5-HT1 and 5-HT1, dual coupling, fibroblasts (mouse), 575 Purinoceptors, pore-forming Paz, poly(A RNA from murine macro- inositol-l,4,5-trisphosphate, calcium mobilization, SH-SY5Y cells, phages, Xenopus oocytes, 93 810 Pyrazinones, substituted, interaction with GABAA receptors, 468 insulin, heterogeneity in tissues, B29,B29’-suberoyl-insulin (rat), 271 Pyruvate, anti-HIV-1 therapy, peripheral neuropathy, PC12 cells, 702 i-like, recognition by phenylaminotetralins, ligand binding, 1232 metabotropic glutamate, developmental changes, cerebellar granule R cells, 981 Raria batesbeiana, biochemical and immunochemical comparison, sax- N-methyl-D-aspartate iphilin and transferrin, 742 discrimination of subtypes, ifenprodil (rat), 851 Receptors long-lasting modification of channel, sulfhydryl redox process acetylcholine, a-bungarotoxin, retina (chick), 1046 (rat), 473 acetyicholine muscarmnic m2 and m3, agonist-induced down-regula- metabotropic glutamate receptors, developmental changes in cer- tion, mRNA and protein in cerebellar granule cells, 940 ebellar granule cells, 981 adenosine A1, G protein activation, brain membranes (cattle), 115 modulation of channel function by nitrendipine, neurons (mouse), adenosine A3, molecular cloning and functional expresaion, tissue 443 muscarinic, blockers of cardiac function, benzoquinoid tyrosine ki- distribution (sheep), 524 nase inhibitors (bullfrog), 595 adenosine A2a, multiple mechanisms, cAMP elevation in PC12 cells, muscarinic acetylcholine, Drosophiki nervous system, immunocyto- 950 chemistry, 716 Ah, cloning and expression of cDNA (human), 911 muscarinic ml, stable allosteric binding, 1171 angiotensin, isoform from turkey adrenal gland, pharmacological muscarinic m2, functional role, smooth muscle of ieum (guinea pig), distinction from mammalian receptors, 1 102 angiotensin II, expression in heart, Xenopus loevis, 277 muscarmnic m3, agonist-induced receptor down-regulation, carboxyl- aryl hydrocarbon, nuclear translocator protein, dioxin action, 511 terminal threonine residues (human), 1158 bradykinin, mixed B1 and B2 pharmacological selectivity (mouse), neurokinin A NK-2, pharmacological characterization, baculovirus/ 346 Sf-21 insect cell system, 356 cannabinoid, binding and analgesic activity, structure-activity rela- neurokinin type 1, [3H]FK888, characterization (guinea pig), 539 tionships, 1008 neuromedin B, antagonists, substituted somatostatin analogues (rat), chimeric muscarinic, epitopes, allosteric interactions, 583 841 dopamine, paradoxical regulation, transfected 293 cells, 371 nicotinic acetylcholine dopamine Dl interaction with curare, selective enhancement (mouse), 237 identical D1A and D1B mRNAs, kidney and brain (opossum), 918 mapping ligand binding sites, chimeric a subunits, 657 retina (goldfish), 1113 volume- and length-dependentloss ofactivity, cycloalkanemethan- dopamine D2, inhibition of potassium current, NG1O8-15 cells, 649 ole, 1219 endothelin NMDA, agonist response kinetics, neurons (rat), 1252 follicular membranes, Xenopus oocytes, 153 nonselective-type endothelin, alternative transcript, brain (rat), 533 modulation of number by phosphoramidon, Swiss 3T3 fibroblasts, opioid 422 differential down- and up-regulation, buprenorphine (rat), 173 subtype expression, saphenous vein (rabbit), 959 in situ interactions with G0, brain (rat), 62 endothelin type A, MMQ cells, 285 opioid o GABAA agonist-induced state, discrimination between opioid peptides and enhancement of currents, activation of cAMP-dependent protein opiate alkaloids, 166 kinase, 1202 gene expression increase by ethanol, neuronal cell lines, 1119 GABA-induced chloride currents, benzodiazepine site agonists, 866 opioid 6 and , interactive down-regulation, neuroblastoma SK-N- interaction, substituted pyrazinones, 468 SH cells, 461 regulation, pregnanolone (chick), 191 opioid L role of subunit, pharmacology (human), 1211 antipeptide antibodies, brain regions and cell line (cattle), 796 U-93631, GABA-induced chloride currents (rat), 860 $-funaltreaxmine labeling, species variations (guinea pig, rat, GABAA subunit, t-butylbicyclophosphoro[Sjthionate binding, re- mouse), 749 gional -y-aminobutyric acid sensitivity (human, rat), 87 molecular cloning and functional expression, brain (rat), 8 GABA.Jbenzodiazepine, role of ‘y subunits (human), 437 purinergic P2u, cytosolic Ca2 and cAMP levels, protein kinase C and GABAA and glycine, positive modulation, inhalation anesthetic glioma cells (rat), 1185 isoflurane, 628 ryanodine, Ca2 release, chlorocresol, 1192 glutamate serotonin, molecular cloning, adenylate cyclase activation (mammal), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kain- 229 ate, cyclothiazide and concanavalin A, 504 somatostatin SSTR4 and SSTR5 (human), 385 Subjectindex 1287

somatostatin subtype 2 SK-N-SH cells, interactive down-regulation, - and #{244}-opioidreceptors, aspartate mutation at residue 89, Na regulation (mouse), 380 461 splice variant, coupling to adenylyl cyclase, 1016 Sodium, regulation of agonist binding, aspartate mutation at residue thromboxane A2, point mutation in 7th hydrophobic domain, agonist 89, somatostatin receptor subtype 2 (mouse), 380 and antagonist binding sites, 934 Sodium channels, batrachotoxin-modified, quaternary ammonium vasamicol, ligand complexes, picomolar dissociation constants, 633 blockers, 667 Red blood cells, Ca2 transport, irreversible modification, phenyl- Sodium-potassium-chloride, inhibition of cotransport, amiloride ana- glyoxal, 399 logues, stimulation of cyclic AMP-dependent protein kinase, 393 Retina Somatostatin analogues, substituted, neuromedin B receptor antago- a-bungarotoxin-sensitive acetylcholine receptors (chick), 1046 fists (rat), 841 truncated dopamine Dl receptor, cloning and characterization (gold- Species differences, (3-funaltrexamine labeling, -opioid receptors, com- fish), 1113 plex-type N-linked oligosaccharides (guinea pig, rat, mouse), 749 Retrovirus, Moloney murine leukemia virus, inhibition of replication, Spleen, a2-adrenergic receptor subtype distribution (human), 70 antiestrogens, 324 Spongistatin 1, inhibition ofmitosis and microtubule assembly, binding Ribavirin, enhanced stimulation, 5’-phosphorylation and anti-HIV of vinblastine to tubulin (sponge), 757 activity, purine 2’--fluoro-2’,3’-dideoxynucleosides, 519 Steroids RNA anesthetic, role of cytochrome P450 in regulation, brain (rat), 1077 a2-adrenergic receptor subtype distribution (human), 70 GABAA receptor regulation, pregnanolone (chick), 191 poly(A, pore-forming P2z purinoceptor, Xenopus oocytes, 93 role of fi subunit, pharmacology, GABAA receptors (human), 1211 RNA, messenger Stomach, a2-adrenergic receptor subtype distribution (human), 70 alterations in dihydrofolate reductase pre-mRNA splicing, 5-fluo- Streptoailoteichus hindustanus, nuclear localization, bleomycin resist- rouraci, quantitative PCR (human), 22 ance protein, mammalian cells, 1135 epoxide hydrolase, distribution and modulation, cytochrome P-450 Substrate, specificity and ligands, calcium, protein kinase isozymes (rat), 990 (insect), 298 glutamate receptor, diversity of expression, live hippocampal CAl Sulfhydryl, voltage-dependent redox process, long-lasting modification, neurons (rat), 308 NMDA receptor channel (rat), 473 Sulfonylurea-sensitive potassium channels, novel subtype, modulation 5-HT1 receptor density and, choroid plexus epithelial cells, mian- by dopamine (rat), 907 serin and l-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane Sumatriptan, cloned human 5-HT10,, and 5-HTIDS, dual coupling, fi- treatment (rat), 725 broblasts (mouse), 575 5-HT1D$, expression in arteries (human, cattle), 242 Synapse, plasma membranes, interaction, tricyclic drug analogs (rat), m2- and m3-muscarinic acetylcholine receptor, agonist-induced down- 129 regulation, cerebellar granule cells, 940 P4502C7, growth hormone and vitamin A, primary hepatocytes (rat), T 997 Tamoxifen, inhibition of replication, retroviral Moloney murine leu- RP-60475, see Introplicine kemia virus, 324 RU486, block, phenobarbital-induced transcriptional activation, cyto- Terfenadine, its metabolites and, delayed rectifier K channel, heart chrome P-450 genes (rat), 775 (human), 1240 Ryanodine 2,3,7,8-Tetrachlorodibenzo-p-dioxin natural congeners, activating and deactivating effects, calcium re- binding in liver, interactions, indolol[3,2-bjcarbazoles and related lease channel of sarcoplasmic reticulum (rabbit), 412 polycyclic aromatic hydrocarbons (rat), 336 receptor-mediated Ca2 release, activator, chlorocresol, 1192 cardiac myocyte intracellular calcium, impaired ventricular contract- S ile responses, isoproterenol and calcium (chick), 1142 Threonine, residues, m3 muscarmnic acetylcholine, agonist-induced Sarcoplasmic reticulum, activating and deactivating effects, calcium down-regulation (human), 1158 release channel, natural ryanodine congeners (rabbit), 412 Threonine 342, role in helix 7, 5HTtD receptor, ligand binding, 882 Saxiphilin, transferrin and, biochemical and immunochemical compar- Thromboxane, A2 receptor, point mutation, 7th hydrophobic domain, ison, Rana catesbeiar&a, 742 934 Seizures, GABAA receptor regulation, pregnanolone (chick), 191 kinase, phosphorylation of enantiomers, carbocyclic analog Selenium, deficiency, electron spin resonance, free radical generation of 2’-deoxyguanosine, HSV-l and uninfected cells, 1258 (rat), 222 Thymidylate synthase, naturally occurring amino acid substitution, Serotonin, molecular cloning of receptor, adenylate cyclase activation functional effects (human), 316 (mammal), 229 Thymocytes, modulation of proliferative response, inhibition of cyclic SH-SY5Y cells, calcium mobilization via the inositol-l,4,5-trisphos- nucleotide phosphodiesterase isoforms, cGMP-elevating agents, phate receptor, induction by inositol-l,3,4,5-tetrakisphosphate, 1027 810 Thymopoietin, preparations, a-cobratoxin and phospholipase A2 activ- Signal transduction ity, 678 comparison of a1-adrenergic receptor subtypes, neuronal cell lines, Tityustoxin-Ka, interaction with a-dendrotoxin binding site, cloned 76 Kvl.2 K channel, 430 endothelin receptors, follicular membranes, Xenopus oocytes, 153 mi-Toxin, stable allosteric binding, ml muscarinic receptors, 1171 multiple pathways, coupling of alB and alD-adrenergic receptors, G Transferrin protein and cell type specific, 784 endocytosis and exocytosis, antimycin A, fl-adrenergic receptors (hu- structural and conformational features, beta-3 adrenoceptors, 1094 man), 364 SK-MG-i cells, transport of (2-chloroethyl)-3-sarcosinamide-1-nitro- saxiphilin and, biochemical and immunochemical comparison, Rana sourea, mediation, epinephrine-sensitive carrier system, 204 catesbeiana, 742 SK-N-MC cells, comparison of a1-adrenergic receptor subtypes, signal Tricyclic drug analogs, interaction with synaptic plasma membranes transduction, 76 (rat), 129 1288 Subject Index

Trimetrexate, mutations leading to antifolate resistance, ethylmetha- Vesicles, secretory, biogenic amine transporters and plasma membrane nesulfonate exposure, CHO cells, 13 interaction, amphetamine derivatives, 1227 d-Tubocurarine, see Curare Vinblastine, binding to tubulin, spongistatin 1, inhibition of mitosis Tubulin, binding of vinblastine, spongistatin 1, inhibition of mitosis (sponge), 757 Vinca, alkaloid resistance, reversal by N-substituted phenoxazines, (sponge), 757 multidrug-resistant cancer cells, 552 Tyrosine hydroxylase, gene expression, metrazole, adrenal gland (rat), Vitamin A, growth hormone and, induction of P4502C7 mRNA, pri- 328 mary hepatocytes (rat), 997 Tyrosine kinase, inhibitors, blockers of cardiac muscarinic receptor Vitamin E, deficiency, electron spin resonance, free radical generation function (bullfrog), 595 (rat), 222

U w

U-93631, rapid decay of GABA-induced chloride currents, recombinant WI-L2 cells, inhibition of 5-phosphoribosyl-l-pyrophosphate synthe- GABAA receptors (rat), 860 tase, 4-amino-8-(/3-D-ribofuranosylamino)pyrmido [5,4-djpyrimi- , anti-HIV-1 therapy, peripheral neuropathy, PC12 cells, 702 dine (human, mouse), 479

V x Xenopus laeuis, angiotensin II receptor expression, heart, 277 Vein, saphenous, expression, endothelin receptor subtypes (rabbit), 959 Vena cava, a2-adrenergic receptor subtype distribution (human), 70 Z Verapamil, block of rapidly activating delayed rectifier K channel, Zinc, inhibition of flux, benzodiazepine-insensitive GABA chloride cloned from human heart, 642 channels, cortical and cerebellar microsacs (rat), 876 Vesamicol, receptor-ligand complexes, picomolar dissociation con- Zonisamide, reductive metabolism, liver microsomal cytochrome P450 stants, kinetic and equilibrium characterization, 633 (human), 216 MOLECULAR PHARMACOLOGY 44:1289-1298

AUTHOR INDEX FOR VOLUME 44

Malkas, L. Antihelicase action of DNA-binding anticancer agents: A Relationship to guanosine-cytidine intercalator binding, 1064 Bahador, A., see Kazanietz, M. G., 298 Abdel-Razzak, Z., Loyer, P., Fautrel, A., Gautier, J.-C., Corcos, L., Bai, R., Cichacz, Z. A., Herald, C. L., Pettit, G. R., and Hamel, E. Turlin, B., Beaune, P., and Guillouzo, A. Cytokines down-regulate Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural expression of major cytochrome P-450 enzymes in adult human product that inhibits mitosis, microtubule assembly, and the bind- hepatocytes in primary culture, 707 ing of vinblastine to tubulin, 757 Abel, P. W., see Feng, F., 926 Bain, C., see Hadingham, K. L., 1211 Abutidze, K., see Kerry, C. J., 142 Ban, C. J., see Wafford, K. A., 437 Adams, M. E., Mintz, I. M., Reily, M. D., Thanabal, V., and Bean, B. Bajaj, R., see Wadler, S., 1070 P. Structure and properties of w-agatoxin IVB, a new antagonist Baker, S. A., see Thomas, E. A., 102 of P-type calcium channels, 681 Bal#{226}zs,R., see Aronica, E., 981 Adesnik, M., see Shaw, P. M., 775 Baldessarini, R. J., see Booth, R. G., 1232 Afar, R, see Quik, M., 680 Ballesta, J. J., see Anand, R., 1046 Agbunag, R. V., see Probst, M. R., 511 Balzarini, J., Karisson, A., and De Clercq, E. Human immunodeficiency Aguayo, L., see Li, C., 871 virus type 1 drug-resistance patterns with different 1-1(2-hydrox- Aharony, D., Little, J., Powell, S., Hopkins, B., Bundell, K. R., Mc- yethoxy)methylj-6-(phenylthio)thyznine derivatives, 694 Pheat, W. L., Gordon, R. D., Hassall, G., Hockney, R., Griffin, R., Banerjee, D., see Fanin, R., 13 and Graham, A. Pharmacological characterization of cloned hu- Banner, C. D., see StrOmstedt, M., 1077 man NK-2 (neurokinin A) receptor expressed in a baculovirus/Sf- Barbour, K. W., see Hughey, C. T., 316 21 insect cell system, 356 Barg, J., see Belcheva, M. M., 173 Ahluwalia, G. S., see Johns, D. G., 519 Barker, E. L., and Sanders-Buch, E. 5-Hydroxytryptamine1c receptor Aiyar, N., see Bergsma, D. J., 277 density and mRNA levels in choroid plexus epithelial cells after Aizenman, E., see Tang, L.-H., 473 treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxy- Alexander, R. W., see Murphy, T. J., 1 phenyl)-2-aminopropane, 725 Alexandersson, M., see Gillner, M., 336 Barnard, E. A., see Kerry, C. J., 142 Allan, P. W., see Bennett, L. L., Jr., 1258 Barnes, P. J., see Miyayasu, K., 539 Amlaiky, N., see Plassat, J.-L., 229 Barry, P. H., see Vandenberg, R. J., 198 Anand, R., Peng, X., Ballesta, J. J., and Lindstrom, J. Pharmacological Bascands, J.-L., Pecher, C., and Girolami, J.-P. Indirect inhibition by characterization of a-bungarotoxin-sensitive acetylcholine recep- tors immunoisolated from chick retina: Contrasting properties of bradykinin of cyclic AMP generation in isolated rat glomeruli and mesangial cells, 818 a7 and a8 subunit-containing subtypes, 1046 Battey, Anderson, R., Smit, M. J., and Van Rensburg, C. E. J. Lysophospholi- J. F., see Orbuch, M., 841 pid-mediated inhibition of Na,K-adenosine triphosphatase is a Baumhaker, Y., Gafni, M., Keren, 0., and Same, Y. Selective and possible mechanism of immunosuppressive activity of cyclosporin interactive down-regulation of - and #{244}-opioidreceptors in human A, 605 neuroblastoma SK-N-SH cells, 461 Angelotti, T. P., Uhler, M. D., and MacDonald, R. L. Enhancement of Bayard, F., see Chailleux, C., 324 recombinant -y-aminobutyric acid type A receptor currents by Beall, H., see Siegel, D., 1128 chronic activation of cAMP-dependent protein kinase, 1202 Bean, B. P., see Adams, M. E., 681 Anthony, N. M., see Blake, A. D., 716 Beatty, M. F., see Maguire, P. A., 1246 Applegren, N., see Bachur, N. R., 1064 Beaumont, K., Kenney, M. A., Young, A. A., and Rink, T. J. High Arai, H., see Siegel, D., 1128 affinity amylin binding sites in rat brain, 493 Areces, L. B., see Kazanietz, M. G., 298 Beaune, P., see Abdel-Razzak, Z., 707 Armstrong, S. G., and Renton, K. W. Mechanism ofhepatic cytochrome Becker, W., see Breiner, M., 271 P450 modulation during Listeria monocytogenes infection in mice, Begleiter, A., and Leith, M. K. Role of NAD(P)H:(quinone acceptor) 677 oxidoreductase (DT-diaphorase) in activation of mitymycin C Arnett, G., see Bennett, L. L., Jr., 1258 under acidic conditions, 210 Aronica, E., Dell’Albani, P., Condorelli, D. F., Nicoletti, F., Hack, N., Belcheva, M. M., Barg, J., McHale, R. J., Dawn, S., Ho, M. T., Ignatova, and Bal#{225}zs,R. Mechanisms underlying developmental changes in E., and Coscia, C. J. Differential down- and up-regulation of rat the expression of metabotropic glutamate receptors in cultured brain opioid receptor types and subtypes by buprenorphine, 173 cerebellar granule cells: Homologous desensitization and interac- Bell, D., see Wang, G. K., 667 tive effects involving N-methyl-D-aspartate receptors, 981 Bell, G. I., see Kong, H., 380 Artymyshyn, R. P., see Boundy, V. A., 677 Bell, G. I., see Raynor, K., 385 Artymyshyn, R. P., see Filtz, T. M., 371 Bell, G. I., see Reisine, T., 1016 Audhya, T., see Lukas, R. J., 680 Bennett, L. L., Jr., Parker, W. B., Allan, P. W., Rose, L. M., Shealy, Audhya, T., see Quik, M., 680 Y. F., Secrist, J. A., III, Montgomery, J. A., Arnett, G., Kirkman, Aylwin, M. L., see Filatov, G. N., 237 R. L., and Shannon, W. M. Phosphorylation of the enantiomers of the carbocyclic analog of 2’-deoxyguanosine in cells infected B with herpes simplex virus type 1 and in uninfected cells. Lack of Babe, M., see Yuasa, S., 895 enantiomeric selectivity with the viral thymidine kinase, 1258 Bachur, N. R., Johnson, R., Yu, F., Hickey, R., Applegren, N., and Berger, F. G., see Hughey, C. T., 316

1289 1290 Author Index

Berger, S. H., see Hughey, C. T., 316 Can, C., see Georgoussi, Z., 62 Bergman, J., see Gillner, M., 336 Carter, D. B., see Dillon, G. H., 860 Bergsma, D. J., Ellis, C., Nuthulaganti, P. R., Nambi, P., Scaife, K., Carter, D. B., see Im, H. K., 468, 866 Kumar, C., and Aiyar, N. Isolation and expression of a novel Carver, L. A., see Dolwick, K. M., 911 angiotensin II receptor from Xenopus laevis heart, 277 Castellano, M. A., Liu, L.-X., Monsma, F. J., Jr., Sibley, D. R., Kapatos, Bertino, J. R., see Fanin, R., 13 G., and Chiodo, L. A. Transfected D2 short dopamine receptors Besch, H. R., Jr., see Humerickhouse, R. A., 412 inhibit voltage-dependent potassium current in neuroblastoma x Bijsterbosch, M. K., see Schouten, D., 486 glioma hybrid (NG1OS-15) cells, 649 Blake, A. D., Anthony, N. M., Chen, H. H., Harrison, J. B., Nathanson, Casy, A. F., see Maguire, P. A., 1246 N. M., and Sattelle, D. B. Drosophila nervous system muscarinic Chailleux, C., Mesange, F., Bayard, F., Prats, A-C., and Faye, J.-C. acetylcholine receptor: Transient functional expression and local- Antiestrogens inhibit the replication of the retroviral Moloney ization by immunocytochemistry, 716 murine leukemia virus in vitro, 324 Blanck, T. J. J., see Canga, L., 1142 Challiss, R. A. J., see Wilcox, R. A., 810 Blaustein, M. P., see Werkman, T. R., 430 Chang, A., see Plopper, C. G., 51 Blin, N., Camoin, L., Maigret, B., and Strosberg, A. D. Structural and Chang, K.-J., see Cheng, H.-F., 533 conformational features determining selective signal transduction Chang, K.-J., see Childers, S. R., 827 in the 33-adrenergic receptor, 1094 Changeux, J.-P., see Quik, M., 678 Blumberg, P. M., see Kazanietz, M. G., 298 Chao, C.-C., see Webb, M. L., 959 Booth, R. G., Wyrick, S. D., Baldessarini, R. J., Kula, N. S., Myers, A. Charness, M. E, Hu, G., Edwards, R H., and Querimit, L. A. Ethanol M., and Mailman, R. B. New c-like receptor recognized by novel increases #{244}-opioidreceptor gene expression in neuronal cell lines, phenylaminotetralins: Ligand binding and functional studies, 1232 1119 Borden, L. A., see Zgombick, J. M., 575 Chaudhry, A., see Granneman, J. G., 264 Boritzki, T. J., see Fry, D. W., 479 Chen, C., see Liu-Chen, L.-Y., 749 Boundy, V. A., Luedtke, R. R., Artymyshyn, R. P., Filtz, T. M., and Chen, H. H., see Blake, A. D., 716 Molinoff, P. B. Development of polyclonal anti-D2 dopamine Chen, R., see Westin, S., 997 receptor antibodies using sequence-specific peptides, 677 Chen, Y., Mestek, A., Liu, J., Hurley, J. A., and Yu, L. Molecular Bradfield, C. A., see Dolwick, K. M., 911 cloning and functional expression of a -opioid receptor from rat Bradford, P. G., Jin, Y., and Hui, P. 1,25-Dihydroxyvitamin D3 en- brain, 8 hances the transcription and expression of the inositol trisphos- Cheng, H.-F., Su, Y.-M., Yeh, J.-R., and Chang, K.-J. Alternative phate receptor gene in HL-60 cells, 292 trasncript of nonselective-type endothelin receptor from rat brain, Branchek,T.A.,seeMichel,M.D., 1165 533 Branchek, T. A., see Zgombick, J. M., 575 Chern, Y., Lai, H.-L., Fong, J. C., and Liang, Y. Multiple mechanisms Brann, M. R., see Ellis, J., 583 for desensitization of A2a adenosine receptor-mediated cAMP Breiner, M., Weiland, M., Becker, W., Miller-Weiland, D., Streicher, elevation in rat pheochromocytoma PC12 cells, 950 R., Fabry, M., and Joost, H. G. Heterogeneity of insulin receptors Chia, L.-S., see Hamel, E., 242 in rat tissues as detected with the partial agonist B29,B29’-sub- Chiang, P. K., see Wolfe, A. D., 1152 eroyl-insulin, 271 Childers, S. R., Fleming, L. M., Selley, D. E., McNutt, R. W., and Breivogel, C. S., see Selley, D. E., 731 Chang, K.-J. BW373U86: A nonpeptidic #{244}-opioidagonist with Bresnick, E., see Sterling, K., 560 novel receptor-G protein-mediated actions in rat brain membranes Brett, R. S., see Dilger, J. P., 1056 and neuroblastoma cells, 827 Brodsky, M., see Zhu, Y.-S., 328 Childers, S. R., see Selley, D. E., 731 Brooker, G., see Munshi, R., 1185 Chiodo, L. A., see Castellano, M. A., 649 Brown, A. M., see Rampe, D., 642, 1240 Chiou, W., see Wu-Wong, J. R., 285 Brown, A. M., see Taglialatela, M., 180 Chiou, W. J., see Wu-Wong, J. R., 422 Brown, M., see McIntyre, P., 346 Chuang, D.-M., see Fukamauchi, F., 940 Buckpitt, A. R., see Plopper, C. G., 51 Chuang, D.-M., see Lin, W.-W., 158 Bundell, K. R., see Aharony, D., 356 Cichacz, Z. A., see Bai, R., 757 Burrows, G. G., see Moebius, F. F., 966 Clark, R. B., see Proll, M. A., 569 Butcher, R. W., see Proll, M. A., 569 Clementi, E., see Zorzato, F., 1192 Cochran, T. L., see Zgombick, J. M., 575 C Condorelli, D. F., see Aronica, E., 981 Calmels, T. P. G., Mistry, J. S., Watkins, S. C., Robbins, P. D., Cook, P. D., see Fry, D. W., 479 McGuire, R., and Lazo, J. S. Nuclear localization of bacterial Cook, R. G., see Quik, M., 678 Streptoalloteichus hindu.stanus bleomycin resistance protein in Cooney,D.A.,seeJohns,D.G.,5l9 mammalian cells, 1135 Corcos, L., see Abdel-Razzak, Z., 707 Cambillau, C., see Gillner, M., 336 Corcos, L., see Shaw, P. M., 775 Camoin, L., see Blin, N., 1094 Cordier, J., see Main, P., 1176 Canga, L., Paroli, L., Blanck, T. J. J., Silver, R. B., and Rilkind, A. B. Coscia, C. J., see Belcheva, M. M., 173 2,3,7,8-Tetrachlorodibenzo-p-dioxin increases cardiac myocyte in- Counillon, L., Scholz, W., Lang, H. J., and Pouyss#{233}gur, J. Pharmaco- tracellular calcium and progressively impairs ventricular contract- logical characterization of stably transfected Na/W antiporter ile responses to isoproterenol and to calcium in chick embryo isoforms using amiloride analogs and a new inhibitor exhibiting hearts, 1142 anti-ischemic properties, 1041 Carfagna, M. A., and Muhoberac, B. B. Interaction of tricyclic drug Coy, D. H., see Orbuch, M., 841 analogs with synaptic plasma membranes: structure-mechanism Cusack, B., Richelson, E., Pang, Y.-P., Zaidi, J., and Kozikowski, A. P. relationships in inhibition of neuronal NajK-ATPase activity, Pharmacological studies on novel neurotensin mimetics: Discovery 129 of a pharmacologically unique agent exhibiting concentration- Caron, M. G., see Nash, S. R., 918 dependent dual effects as antagonist and agonist, 1036 Author Index 1291

0 Farb, D. H., see Friedman, L., 191 Fautrel, A., see Abdel-Razzak, Z., 707 Dage, R. C., see Rampe, D., 642, 1240 Faye, J.-C., see Chailleux, Davies, M. F., Maguire, P. A., and Loew, G. H. Zinc selectively inhibits C., 324 Fedida, D., see Rampe, D., 642 flux through benzodiazepine-insensitive -y-aminobutyric acid chlo- ride channels in cortical and cerebellar microsacs, 876 Feldman, R. D., and Dixon, S. J. Inhibition of NA-K-C cotransport by amiloride analogues is associated with stimulation of cyclic AMP- Davison, M. D., see Lampe, R. A., 451 Dawn, S., see Belcheva, M. M., 173 dependent protein kinase, 393 Feng, F., Abel, P. W., Seofield, M., Liu, F., Wolff, D. W., and Jeffries, DeBernardi, M. A., see Munshi, R., 1185 De Clercq, E., see Balzarini, J., 694 W. B. Heterogeneous expression of a1-adrenoceptor subtypes among rat nephron segments, 926 Dc Clercq, E., see Jansen, R. W., 1003 DeFeo, P. A., see Lampe, R. A., 451 Fernstr#{246}m, B., see Gillner, M., 336 Dell’Albani, P., see Aronica, E., 981 Filatov, G. N., Aylwin, M. L., and White, M. M. Selective enhancement de S. Otero, A., and Sweitzer, N. M. Benzoquinoid tyrosine kinase of the interaction of curare with the nicotinic acetylcholine recep- inhibitors are potent blockers of cardiac muscarinic receptor func- tor, 237 tion, 595 Filtz, T. M., Artymyshyn, R P., Guan, W., and Molinoff, P. B. Devane, W. A., see MacIde, K., 498 Paradoxical regulation of dopamine receptors in transfected 293 DeYoung, M. B., see Perez, D. M., 784 cells, 371 Diamond, I., see Krause, S. W., 1021 Filtz, T. M., see Boundy, V. A., 677 Dicker, A. P., see Fanin, R., 13 Fink, J. S., see Linden, J., 524 Dilger, J. P., Brett, R. S., and Mody, H. I. The effects of isoflurane on Fisher, S. M., see Webb, M. L., 959 acetylcholine receptor channels: 2. Currents elicited by rapid per- Fitzgerald, G. A., see Funk, C. D., 934 fusion of acetylcholine, 1056 Fleming, L. M., see Childers, S. R., 827 Dillon G. H., Im, H. K., Hamilton, B. J., Carter, D. B., Gammill, R. B., Fong, J. C., see Chern, Y., 950 Judge, T. M., and Im, W. B. U-93631 causes rapid decay of -y- Forray,C.,seeMichel,M.D., 1165 aminobutyric acid-induced chloride currents in recombinant rat -y- Frail, D. E., Manelli, A. M., Witte, D. G., Lin, C. W., Steffey, M. E., aminobutyric acid type A receptors, 860 and MacKenzie, R. G. Cloning and characterization of a truncated Dixon, S. J., see Feldman, R. D., 393 dopamine Dl receptor from goldfish retina: Stimulation of cyclic Doctor, B. P., see Wolfe, A. D., 1152 AMP production and calcium mobilization, 1113 Dolnick, B. J., see Wu, X.-P., 22 Franklin, S. 0., see Zhu, Y.-S., 328 Dolwick, K. M., Schmidt, J. V., Carver, L. A., Swanson, H. I., and Freedman, J. E., see Lin, Y.-J., 907 Bradfield, C. A. Cloning and expression of a human An receptor French, C. R., see Vandenberg, R. J., 198 eDNA, 911 Fridland, A., see Gong, Y.-F., 30 Drewe, J. A., see Taglialatela, M., 180 Friedman, L., Gibbs, T. T., and Farb, D. H. -y-Aminobutyric acidA Driscoll, J. S., see Johns, D. G., 519 receptor regulation: chronic treatment with pregnanolone uncou- Dubyak, G. R., see Nuttle, L. C., 93 ples allosteric interactions between steroid and benzodiazepine recognition sites, 191 E Fry, D. W., Boritzki, T. J., Jackson, R C., Cook, P. D., and Leopold, Eason, M. G., and Liggett, S. B. Human a2-adrenergic receptor subtype W. R. Inhibition of 5-phosphoribosyl-1-pyrophosphate synthetase distribution: widespread and subtype-selective expression of by the monophosphate metabolite of 4-amino-8-($-D-ribofurano- a2ClO, a2C4, and a2C2 mRNA in multiple tissues, 70 sylamino)pyrimido-[5,4-d] : A novel mechanism for an- Eberwine, J. H., see Mackler, S. A., 308 titumor activity, 479 Edwards, R. H., see Charness, M. E., 1119 Fryar,N.,seeWolfe,A.D., 1152 Ehlert, F. J., see Thomas, E. A., 102 Fukamauchi, F., Saunders, P. A., Hough, C., and Chuang, D.-M. Eiden, L. E., see MacArthur, L., 545 Agonist-induced down-regulation and antagonist-induced up-reg- Eipper, B. A., see Mueller, G. P., 972 ulation of m2- and m3-muscarinic acetylcholine receptor mRNA El-Bizri, H., see Quik, M., 680 and protein in cultured cerebellar granule cells, 940 Ellis, C., see Bergsma, D. J., 277 Funk, C. D., Furci, L., Moran, N., and Fitzgerald, G. A. Point mutation Ellis, J., Seidenberg, M., and Brann, M. R. Use of chimeric musarinic in the seventh hydrophobic domain of the human thromboxane A2 receptors to investigate epitopes involved in allosteric interctions, receptor allows discrimination between agonist and antagonist 583 binding sites, 934 El-Moatassim, C., see Nuttle, L. C., 93 Furci, L., see Funk, C. D., 934 Emmick, J. T., see Humerickhouse, R. A., 412 Fuss, M., see Lorenzen, A., 115 Eriks, J. C., Van der Goot, H., and Timmerman, H. New activation G model for the histamine H2 receptor, explaining the activity of the different classes of histamine H2 receptor agonists, 886 Gafni, M., see Baumhaker, Y., 461 Esbenshade, T. A., Han, C., Murphy, T. J., and Minneman, K. P. Gammill, R. B., see Dillon, G. H., 860 Comparison of a1-adrenergic receptor subtypes and signal trans- Gammill, R. B., see Im, H. K., 468 duction in SK-N-MC and NB41A3 neuronal cell lines, 76 Garcia-S#{227}inz, J. A., and Romero-Avila, M. T. Characterization of the Evans, C. J., see Von Zastrow, M., 166 alA-adrenoceptors of guinea pig liver membranes: Studies using 5- [3HJ methylurapidil, 589 F Gautier, J.-C., see Abdel-Razzak, Z., 707 Fabry, M., see Breiner, M., 271 Geertsen, S., see Quik, M., 680 Fan, E., see Hamel, E., 242 Georgoussi, Z., Can, C., and Milligan, G. Direct measurements of in Fanin, It, Banerjee, D., Volkenandt, M., Waltham, M., Li, W. W., situ interactions of rat brain opioid receptors with the guanine Dicker, A. P., Schweitzer, B. I., and Bertino, J. R. Mutations nucleotide-binding protein G0, 62 leading to antifolate resistance in Chinese hamster ovary cells Gerzon, K., see Humerickhouse, R. A., 412 after exposure to the alkylating agent ethylmethanesulfonate, 13 Ghirnikar, R. B., see Krauss, S. W., 1021 1292 Author Index

Gibbs, T. T., see Friedman, L., 191 Hassall, G., see Aharony, D., 356 Gibson, N. W., see Siegel, D., 1128 Hawthorn, M., see Kim, W.-K., 405 Gillner, M., Bergman, J., Cambillau, C., Alexandersson, M., Fernstr#{246}m, Hen, R., see Plassat, J.-L., 229 B., and Gustafsson, J.-A. Interactions of indolo[3,2-bjcarbazoles Herald, C. L., see Bai, R., 757 and related polycyclic aromatic hydrocarbons with specific binding Herman, J. L., see Lampe, R. A., 451 sites for 2,3,7,8,-tetrachlorodibenzo-p-dioxin in rat liver, 336 Hickey, R., see Bachur, N. R., 1064 Gioannini, T. L., Yao, Y. H., Miller, J. M., Taylor, L. P., and Simon, Hill, W. A., see Wood, S. C., 1219 E. J. Antisera against peptides derived from a purified z-opioid Hille, B., see Mackie, K., 498 binding protein recognize the protein as well as -opioid receptors Ho, K. L., see Sterling, K., 560 in brain regions and a cell line, 796 Ho, M. T., see Belcheva, M. M., 173 Girolami, J.-P., see Bascands, J.-L., 818 Hobbs, G. A., see Keilbaugh, S. A., 702 Glossman, H., see Moebius, F. F., 966 Hockney, R., see Aharony, D., 356 Glowinski, J., see Mann, P., 1176 Hoffman, B. B., see Hu, Z.-W., 1105 Godinot, N., see Nash, S. R., 918 Hopkins, B., see Aharony, D., 356 Goeptar, A. R, Te Koppele, J. M., Lamme, E. K., Piqu#{233},J. M., and Horn, M. B., see Lampe, R. A., 451 Vermeulen, N. P. E. Cytochrome P450 2Bl-mediated one-electron Horton, J. K., Thimmaiah, K. N., Harwood, F. C., Kuttesch, J. F., and reduction of adriamycin: A study with rat liver microsomes and Houghton, P. J. Pharmacological characterization of N-substituted purified enzymes, 1267 phenoxazines directed toward reversing ymca alkaloid resistance Goldstein, G., see Lukas, R. J., 680 in multidrug-resistant cancer cells, 552 Goldstein, G., see Quik, M., 680 Hough, C., see Fukamauchi, F., 940 Gong, Y.-F., Srinivas, R V., and Fridland, A. 5-Amino-4-imidazolecar- Houghton, P. J., see Horton, J. K., 552 boxamide riboside potentiates the metabolism and anti-human Howlett, A. C., see Melvin, L. S., 1008 immunodeficiency virus activity of 2’,3’-dideoxyinosine, 30 Hu, G., see Charness, M. E., 1119 Goodnight, J., see Kazanietz, M. G., 298 Hu, Z.-W., and Hoffman, B. B. Cycloheximide induces the adre- Gordon, A. S., see Krauss, S. W., 1021 nergic receptor gene by activation of transcription in DDT1 MF-2 Gordon, R. D., see Aharony, D., 356 smooth muscle cells, 1105 Graham, A., see Aharony, D., 356 Huang, T., see Zhu, Y.-S., 328 Graham, R. M., see Perez, D. M., 784 Hughey, C. T., Barbour, K. W., Berger, F. G., and Berger, S. H. Granneman, J. G., Lahners, K. N., and Chaudhry, A. Characterization Functional effects of a naturally occurring amino acid substitution of the human fl3-adrenergic receptor gene, 264 in human thymidylate synthase, 316 Hui, P., see Bradford, P. G., 292 Green, R. D., see Yu, H. J., 689 Humerickhouse, R. A., Besch, H. R., Jr., Gerzon, K., Ruest, L., Sutko, Greenblatt, E. P., see Harrison, N. L., 628 J. L., and Emmick, J. T. Differential activating and deactivating Greif, G. J., see Lin, Y.-J., 907 Griffin, R., see Aharony, D., 356 effects of natural ryanodine congeners on the calcium release channel of sarcoplasmic reticulum: Evidence for separation of Guan, W., see Filtz, T. M., 371 effects at functionally distinct sizes, 412 Guillouzo, A., see Abdel-Razzak, Z., 707 Hurley, J. A., see Chen, Y., 8 Gustafson, T. A., see Werkman, T. R., 430 Husten, E. J., see Mueller, G. P., 972 Gustafsson, J.-A., see Gillner, M., 336 Gustafsson, J.-A., see Str#{246}mstedt, M., 1077 I Gustafsson, J.-A., see Westin, S., 997 Ignatova, E., see Belcheva, M. M., 173 H Im, H. K., Im, W. B., Hamilton, B. J., Carter, D. B., and Vonvoigtlan- der, P. F. Potentiation of -y-aminobutyric acid-induced chloride Hack, N., see Aronica, E., 981 currents by various benzodiazepline site agonists with the al’y2, Hadingham, K. L., Wingrove, P. B., Wafford, K. A., Ban, C., Kemp, $2-y2 and a12y2 subtypes of cloned -y-aminobutyric acid type A J. A., Palmer, K. J., Wilson, A. W., Wilcox, A. S., Sikela, J. M., receptors, 866 Ragan, C. I., and Whiting, P. J. Role of the $ subunit in determin- Im, H. K., Im, W. B., Judge, T. M., Gammill, T. B., Hamilton, B. J., ing the pharmacology of human ‘y-aminobutyric acid type A recep- Carter, D. B., and Pregenzer, J. F. Substituted pyrazinones, a new tore, 1211 class of allosteric modulators for ‘y-aminobutyric acidA receptors, Hallam, S., see Wadler, S., 1070 468 Hamel, E., Fan, E., Linville, D., Ting, V., Villemure, J.-G., and Chia, Im, H. K., see Dillon, G. H., 860 L.-S. Expression of mRNA for the serotonin 5- Im, W. B., see Dillon, G. H., 860 hydroxytryptaminelD[cflO]fl[cfl] receptor subtype in human and Im, W. B., see Im, H. K., 468, 866 bovine cerebral arteries, 242 Inouye, N., see Yuasa, S., 895 Hamel, E., see Bai, R., 757 Inturrisi, C. E., see Zhu, Y.-S., 328 Hamilton, B. J., see Dillon, G. H., 860 Hamilton, B. J., see Im, H. K., 468, 866 J Han, C., see Esbenshade, T. A., 76 Jackson, R. C., see Fry, D. W., 479 Hand, K., see Rogers, G. A., 633 Jansen, R. W., Schols, D., Pauwels, R., De Clercq, E., and Meijer, D. Hankinson, 0., see Probst, M. R., 511 K. F. Novel, negatively charged, human serum albumins display Hanna, P. M., see Kadiiska, M. B., 222 potent and selective in vitro anti-human immonodeficiency virus Hanner, M., see Moebius, F. F., 966 type 1 activity, 1003 Harrison, J. B., see Blake, A. D., 716 Jeffreis, W. B., see Feng, F., 926 Harrison, N. L., Kugler, J. L., Jones, M. V., Greenblatt, E. P., and Jensen, R. T., see Orbuch, M., 841 Pritchett, D. B. Positive modulation of human -y-aminobutyric Jin, Y., see Bradford, P. G., 292 acid type A and glycine receptors by the inhalation anesthetic Johansen, T. E., see Yang, J., 1158 isoflurane, 628 Johns, D. G., Ahluwalia, G. S., Cooney, D. A., Mitsuya, H., and Driscoll, Harwood, F. C., see Horton, J. K., 552 J. S. Enhanced stimulation by ribavirin of the 5’-phosphorylation Authorlndex 1293

and anti-human immunodeficiency virus activity of purmne 2’-fi- of nucleoside transporters, 1021 fluoro-2’,3’ -dideoxynucleosides, 519 Kucharewicz, S. A., see Zgombick, J. M., 575 Johns, R. A., see Rengasamy, A., 124 Kugler, J. L., see Harrison, N. L., 628 Johnson, G. L., see Russell, M., 255 Kula, N. S., see Booth, R. G., 1232 Johnson, M. R., see Melvin, L. S., 1008 Kumar, C., see Bergsma, D. J., 277 Johnson, R., see Bachur, N. R., 1064 Kumar, C. S., Nuthulaganti, P., Pullen, M., and Nambi, P. Novel Jones, M. V., see Harrison, N. L., 628 endothelin receptors in the follicular membranes ofXenopus loevis Joost, H. G., see Breiner, M., 271 oocytes mediate calcium responses by signal transduction through Jordan, S. J., see Kadiiska, M. B., 222 gap junctions, 153 Judge, T. M., see Dillon, G. H., 860 Kuttesch, J. F., see Horton, J. K., 552 Judge, T. M., see Im, H. K., 468 L K Lagarde, M., see Marcoz, P., 1027 Kadiiska, M. B., Hanna, P. M., Jordan, S. J., and Mason, R. P. Electron Lahners, K. N., see Granneman, J. G., 264 spin resonance evidence for free radical generation in copper- Lai, H.-L., see Chern, Y., 950 treated vitamin E- and selenium-deficient rats: in vivo spin-trap- Lamme, E. K., see Goeptar, A. R., 1267 ping investigation, 222 Lampe, R A., DeFeo, P. A., Davison, M. D., Young, J., Herman, J. L., Kamal, J. J., see Maguire, P. A., 1246 Spreen, R C., Horn, M. B., Mangano, T. J., and Keith, R A. Kapatos, G., see Castellano, M. A., 649 Isolation and pharmacological characterization of w-grammatoxin Karisson, A., see Balzarini, J., 694 Sb, a novelpeptide inhibitor ofneuronal voltage-sensitive calcium Kasai, M., see Siegel, D., 1128 channel responses, 451 Kazanietz, M. G., Areces, L. B., Bahador, A., Mischak, H., Goodnight, Lang, H. see Counillon, L., 1041 J., Mushinski, J. F., and Blumberg, P. M. Characterization of Lavelle, F., see Poddevin, B., 767 ligand and substrate specificity for the calcium-dependent and Law, J. S., see Calmels, T. P. G., 1135 calcium-independent protein kinase C isozymes, 298 Leith, M. K., see Begleiter, A., 210 Keilbaugh, S. A., Hobbs, G. A., and Simpson, M. V. Anti-human Leopold, W. R., see Fry, D. W., 479 immunodeficiency virus type 1 therapy and peripheral neuropathy: Li, C., Aguayo, L., Peoples, R. W., and Weight, F. F. Ethanol inhibits Prevention of 2’,3’-dideoxycytidine toxicity in PC12 cells, a neu- a neuronal ATP-gated ion channel, 871 ronal model, by uridine and pyruvate, 702 Li, W. W., see Fanin, R., 13 Keith, D. E., Jr., see Von Zastrow, M., 166 Li, Y., Llewellyn, L., and Moczydlowski, E. Biochemical and immuno- Keith, R. A., see Lampe, R. A., 451 chemical comparison ofsaxiphilin and transferrin, two structurally Kemp, J. A., see Hadingham, K. L., 1211 related plasma proteins from Rana Catesbelana, 742 Kemp, J. A., see Priestley, T., 1252 Liang, J.-S., see Max, S. I., 1171 Kemp, J. A., see Wafford, K. A., 437 Liang, Y., see Chern, Y., 950 Kenney, M. A., see Beaumont, K., 493 Liao, J.-F., and Perkins, J. P. Differential effects of antimycin A on Keren, 0., see Baumhaker, Y., 461 endocytosis and exocytosis of transferrin also are observed for Kerker, J., see Michel, M. D., 1165 internaliztion and externalization of -adrenergic receptors, 364 Kerry, C. J., Sudan, H. L., Abutidze, K., Mellor, I. R., Barnard, E. A., Liedtke, R. R., see Boundy, V. A., 677 and Usherwood, P. N. R. Reconstitution of glutamate receptor Liggett, S. B., see Eason, M. G., 70 proteins purified from Xenopus central nervous system into arti- Lin,C.W.,seeFrail,D.E., 1113 ficial bilayers, 142 Lin, C. W., see Wu-Wong, J. R., 285 Kim, W.-K., Hawthorn, M., and Rabin, R. A. Differential effects of Lin, W.-W., and Chuang, D.-M. Endothelin- and ATP-induced inhi- chronic ethanol exposure on ATP- and bradykinin-induced in- bition of adenylyl cyclase activity in C5 glioma cells: role of G1 and creases in intracellular calcium levels in PC-12 cells, 405 calcium, 158 Kirkman, R. L., see Bennett, L. L., Jr., 1258 Lin, Y.-J., Greif, G. J., and Freedman, J. E. Multiple sulfonylurea- Kitada, M., see Nakasa, H., 216 sensitive potassium channels: A novel subtype modulated by do- Kiuchi, M., see Nakasa, H., 216 pamine, 907 Klatt, P., see Schmidt, K., 615 Linden, J., Taylor, H. E., Robeva, A. S., Tucker, A. L., Stehle, J. H., Kobilka, B. K., see Suryanarayana, S., 111 Rivkees, S. A., Fink, J. S., and Reppert, S. M. Molecular cloning Koller, K. J., see MacArthur, L., 545 and functional expression of a sheep A adenosine receptor with Komiya, M., see Nakasa, H., 216 widespread tissue distribution, 524 Kong, H., Raynor, K., Yasuda, K., Bell, G. I., and Reisine, T. Mutation Lindstrom, J., see Anand, R., 1046 of an aspartate at residue 89 in somatostatin receptor subtype 2 Linville, D., see Hamel, E., 242 prevents Na regulation of agonist binding but does not alter Little, J., see Aharony, D., 356 receptor-G protein association, 380 Liu, C., see Wilcox, R. A., 810 Kong, H., see Raynor, K., 385 Liu, E. C. K., see Webb, M. L., 959 Kong, H., see Reisine, T., 1016 Liu, F., see Feng, F., 926 Kornreich, W. D., see Rogers, G. A., 633 Liu, J., see Chen, Y., 8 Koropatnick, J., and Pearson, J. Altered cisplatin and cadmium resist- Liu, L.-X., see Castellano, M. A., 649 ance and cell survival in Chinese hamster ovary cells expressing Liu-Chen, L.-Y., Chen, C., and Phillips, C. A. -[3H]Funaltrexamine- mouse metallothionein, 44 labeled -opioid receptors: Species variations in molecular mass Korpi, E. R., and L#{252}ddens,H. Regional -y-aminobutyric acid sensitivity and glycosylation by complex-type, N-linked oligosaccharides, 749 of t-butylbicyclophosphoro[S)thionate binding depends on ‘y- Llewellyn, L., see Li, Y., 742 aminobutyric acid,, receptor a subunit, 87 Loew, G. H., see Davies, M. F., 876 Kozikowski, A. P., see Cusack, B., 1036 Loew, G. H., see Maguire, P. A., 1246 Krause, S. W., Ghirnikar, R. B., Diamond, I., and Gordon, A. S. Logsdon, C. D., see Yang, J., 1158 Inhibition of adenosine uptake by ethanol is specific for one class Lorenzen, A., Fuss, M., Vogt, H., and Schwabe, U. Measurement of 1294 Author Index

guanine nucleotide-binding protein activation by A1 adenosine pharmacological selectivity, 346 receptor agonists in bovine brain membranes: stimulation of guan- McNutt, R. W., see Childers, S. R., 827 osine-5’-O-(3-[S]thio)triphosphate binding, 115 McPheat, W. L., see Aharony, D., 356 Loyer, P., see Abdel-Razzak, Z., 707 Meijer, D. K. F., see Jansen, R. W., 1003 Lucero, L., see Lukas, R. J., 680 Mellor, I. R., see Kerry, C. J., 142 L#{252}ddens,H., see Korpi, E. R., 87 Melvin, L. S., Milne, G. M., Johnson, M. R., Subramaniam, B., Wilken, Luetje, C. W., Piattoni, M., and Patrick, J. Mapping of ligand binding G. H., and Howlett, A. C. Structure-activity relationships for sites of neuronal nicotinic acetylcholine receptors using chimeric cannabinoid receptor-binding and analgesic activity: Studies of a subunits, 657 bicyclic cannabinoid analogs, 1008 Lukas, R. J., Audhya, T., Goldstein, G., and Lucero, L. Interactions of Mesange, F., see Chailleux, C., 324 the thymic polypeptide hormone thymopoietin with neuronal nic- Mestek, A., see Chen, Y., 8 otinic a-bungarotoxin binding sites and with muscle-type, but not Michel, M. C., Kerker, J., Branchek, T. A., and Forray, C. Selective ganglia-type, nicotinic acetylcholine receptor ligand-gated ion irreversible binding of chloroethylclonidine at a,- and a2-adreno- channels, 680 ceptor subtypes, 1165 Lynch, J., see Webb, M. L., 959 Miksicek, R. J. Commonly occurring plant flavonoids have estrogenic activity, 37 M Miller, J. M., see Gioannini, T. L., 796 Ma, H., see Yu, H. J., 689 Miller, K. W., see Wood, S. C., 1219 MacArthur, L., Koller, K. J., and Eiden, L. E. Enkephalin gene tran- Milligan, G., see Georgoussi, Z., 62 scription in bovine chromaffin cells is regulated by calcium and Milne, G. M., see Melvin, L. S., 1008 protein kinase A signal transduction pathways: identification of Minneman, K. P., see Esbenshade, T. A., 76 DNase I-hypersensitive sites, 545 Minneman, K. P., see Zhong, H., 1085 MacDonald, P. ., see Str#{246}mstedt, M., 1077 Mintz, I. M., see Adams, M. E., 681 MacDonald, R. L., see Angelotti, T. P., 1202 Mischak, H., see Kazanietz, M. G., 298 MacKenzie, R. G., see Frail, D. E., 1113 Mistry, J. S., see Calmels, T. P. G., 1135 Mackie, K., Devane, W. A., and Hille, B. Anandamide, an endogenous Mitsuya, H., see Johns, D. G., 519 cannabinoid, inhibits calcium currents as a partial agonist in Nl8 Miyayasu, K., Mak, J. C. W., Nishikawa, M., and Barnes, P. J. neuroblastoma cells, 498 Characterization of guinea pig pulmonary neurokinin type 1 recep- Mackler, S. A., and Eberwine, J. H. Diversity of glutamate receptor tors using a novel antagonist ligand, [3H]FK888, 539 subunit mRNA expression within live hippocampal CAl neurons, Moczydlowski, E., see Li, Y., 742 308 Mode, A., see Westin, S., 997 Magnuson, S. R., see Wu-Wong, J. R., 285 Mody, H. I., see Dilger, J. P., 1056 Maguire, P. A., Perez, J. J., Tsai, N. F., Rodriguez, L., Beatty, M. F., Moebius, F. F., Burrows, G. G., Hanner, M., Schmid, E., Striessnig, J., Villar, H. 0., Kamal, J. J., Upton, C., Casy, A. F., and Loew, G. and Glossmann, H. Identification of a 27-kDa high affinity phen- H. Molecular mechanism of #{244}-selectivity of indole analogs in ylalkylamine-binding polypeptide as the a, binding site by photo- nonpeptide opioids, 1246 affinity labeling and ligand-directed antibodies, 966 Maguire, P. A., see Davies, M. F., 876 Mok, W. M., see Wang, G. K., 667 Mahan, L. C., see Raynor, K., 385 Molinoff, P. B., see Boundy, V. A., 677 Maigret, B., see Blin, N., 1094 Molinoff, P. B., see Filtz, T. M., 371 Mailman, R. B., see Booth, R. G., 1232 Monshizadegan, H., see Webb, M. L., 959 Mains, R. E., see Mueller, G. P., 972 Monsma, F. J., Jr., see Castellano, M. A., 649 Mak, J. C. W., see Miyayasu, K., 539 Montgomery, J. A., see Bennett, L. L., Jr., 1258 Malapetsa, A., see Ne, A. J., 204 Moran, N., see Funk, C. D., 934 Malkas, L., see Bachur, N. R., 1064 Moreau, J.-P., see Orbuch, M., 841 Manelli, A. M., see Frail, D. E., 1113 Morin, D., see Plopper, C. G., 51 Mangano, T. J., see Lampe, R. A., 451 Mrozinski, J. E., Jr., see Orbuch, M., 841 Mantey, S. A., see Orbuch, M., 841 Mueller, G. P., Husten, E. J., Mains, R. E., and Eipper, B. A. Peptide Mao, X., see Wadler, S., 1070 a-amidation and peptidylglycine a-hydroxylating monooxygenase: Marcoz, P., Prigent, A. F., Lagarde, M., and N#{233}moz,G. Modulation of Control by disulfiram, 972 rat thymocyte proliferative response through the inhibition of Muhoberac, B. B., see Carfagna, M. A., 129 different cyclic nucleotide phosphodiesterase isoforms by means Muller, J., see Schouten, D., 486 of selective inhibitors and cGMP-elevating agents, 1027 Mtiller-Weiland, D., see Breiner, M., 271 Maren, T. H., Wynns, G. C., and Wistrand, P. J. Chemical properties Munshi, R., DeBernardi, M. A., and Brooker, G. P2-purinergic recep- of carbonic anydrase IV, the membrane-bound , 901 tors on C6-2B rat glioma cells: Modulation of cytosolic Ca2 and Mann, P., Stella, N., Cordier, J., Glowinski, J., and Pr#{233}mont,J. Role cAMP levels by protein kinase C, 1185 of arachidonic acid and glutamate in the formation of inositol Murphy, T. J., Nakamura, Y., Takeuchi, K., and Alexander, R. W. A phosphates induced by noradrenalin in striatal astrocytes, 1176 cloned angiotensin receptor isoform from the turkey adrenal gland Mason, R. P., see Kadiiska, M. B., 222 is pharmacologically distinct from mammalian angiotensin recep- Max, S. I., Liang, J.-S., and Potter, L. T. Stable allosteric binding of tors, 1 mi-toxin to ml muscarmnic receptors, 1171 Murphy, T. J., see Esbenshade, T. A., 76 Mayer, B., see Schmidt, K., 615 Murray, M., see Westin, S., 997 Mayer, M. L., see Wong, L. A., 504 Mushinski, J. F., see Kazanietz, M. G., 298 McCarthy, K. D., see Shao, Y., 247 Myers, A. M., see Booth, R. G., 1232 McGuire, R., see Calmels, T. P. G., 1135 N McHale, R. J., see Belcheva, M. M., 173 McIntyre, P., Phillips, E., Skidmore, E., Brown, M., and Webb, M. Nahorski, S. R., see Wilcox, R. A., 810 Cloned murine bradykinin receptor exhibits a mixed B1 and B2 Nakamura, Y., see Murphy, T. J., 1 Authorlndex 1295

Nakasa, H., Komiya, M., Ohmori, S., Rikihisa, T., Kiuchi, M., and Buckpitt, A. R. Postnatal changes in the expression and distribu- Kitada, M. Characterization of human liver microsomal cyto- tion of pulmonary cytochrome P450 monooxygenases during Clara chrome P450 involved in the reductive metabolism of zonisamide, cell differentiation in rabbits, 51 216 Poddevin, B., Riou, J.-F., Lavelle, F., and Pommier, Y. Dual topoisom- Nambi, P., see Bergsma, D. J., 277 erase I and II inhibition by intoplicine (RP-60475), a new antitut- Nambi, P., see Kumar, C. S., 153 mor agent in early clinical trials, 767 Nash, S. R., Godinot, N., and Caron, M. G. Cloning and characteriza- Pommier, Y., see Poddevin, B., 767 tion of the opossum kidney cell Dl dopamine receptor: Expression Potter, B. V. L., see Wilcox, R. A., 810 of identical D1A and D1B dopamine receptor mRNAs in opossum Potter, L. T., see Max, S. I., 1171 kidney and brain, 918 Pouyss#{233}gur, J., see Counillon, L., 1041 Nathanson, N. M., see Blake, A. D., 716 Powell S., see Aharony, D., 356 N#{233}moz,G., see Marcoz, P., 1027 Prats, A-C., see Chailleux, C., 324 Nicoletti, F., see Aronica, E., 981 Pregenzer, J. F., see Im, H. K., 468 Nishikawa, M., see Miyayasu, K., 539 Pr#{233}mont, J., see Mann, P., 1176 Noe, A. J., Malapetsa, A., and Panasci, L. C. Transport of (2-chloroe- Priestley, T., and Kemp, J. A. Agonist response kinetics of N-methyl- thyl)-3-sarcosinamide-l-nitrosourea in the human glioma cell line D-aspartate receptors in neurons cultured from rat cerebral cortex SK-MG-i is mediated by an epinephrine-sensitive carrier system, and cerebellum: Evidence for receptor heterogeneity, 1252 204 Prigent, A. F., see Marcoz, P., 1027 Nuthulaganti, P., see Kumar, C. S., 153 Pritchett, D. B., see Harrison, N. L., 628 Nuthulaganti, P. R., see Bergsma, D. J., 277 Probst, M. R., Reisz-Porszasz, S., Agbunag, R. V., Ong, M. S., and Nuttle, L. C., El-Moatassim, C., and Dubyak, G. R. Expression of the Hankinson, 0. Role of the aryl hydrocarbon receptor nuclear pore-forming P2z purinoreceptor in Xenopus oocytes injected with translocator protein in aryl hydrocarbon (dioxin) receptor action, poly(A) RNA from murine macrophages, 93 511 Proll, M. A., Clark, R. B., and Butcher, R. W. $2-Adrenergic receptor 0 mutants reveal structural requirements for the desensitization O’Carroll, A.-M., see Raynor, K., 385 observed with long term epinephrine treatment, 569 Ohmori, S., see Nakasa, H., 216 Pullen, M., see Kumar, C. S., 153 Omiecinski, C. J., see Schilter, B., 990 Ong, M. S., see Probst, M. R., 511 Q Opgenorth, T. J., see Wu-Wong, J. R., 422 Querimit, L. A., see Charness, M. E., 1119 Orbuch, M., Taylor, J. E., Coy, D. H., Mrozinski, J. E., Jr., Mantey, S. Quik, M., Afar, R., Geertsen, S., Audhya, T., Goldstein, G., and Trifaro, A., Battey, J. F., Moreau, J.-P., and Jensen, R. T. Discovery of a J. M. Thymopoietin, a thymic polypeptide regulates nicotinic a- novel class of neuromedin B receptor antagonists, substituted bungarotoxin sites in chromaffin cells in culture, 680 somatostatin analogues, 841 Quik, M., Cook, R. G., Revah, F., Changeux, J.-P., and Patrick, J. Osman, R., see Smolyar, A., 882 Commentary: Presence of a-cobratoxin and phospholipase A2 ac- tivity in thymopoietin preparations, 678 P Quik, M., El-Bizri, H., Audhya, T., and Goldstein, G. Thymopoietin, a Palmer, K. J., see Hadingham, K. L., 1211 potent antagonist at nicotinic receptors in C2 muscle cell cultures, Panasci, L. C., see Ne, A. J., 204 680 Pang, Y.-P., see Cusack, B., 1036 Parker, W. B., see Bennett, L. L., Jr., 1258 R Paroli, L., see Canga, L., 1142 Rabin, R. A., see Kim, W.-K., 405 Patrick, J., see Luetje, C. W., 657 Raess, B. U. Irreversible modifiction of red cell Ca2 transport by Patrick, J., see Quik, M., 678 phenylglyoxal, 399 Pauwels, R., see Jansen, R. W., 1003 Ragan, C. I., see Hadingham, K. L., 1211 Pearson, J., see Koropatnick, J., 44 Rajendra, S., see Vandenberg, R. J., 198 Pecher, C., see Bascands, J.-L., 818 Rampe, D., Wible, B., Brown, A. M., and Dage, R. C. Effects of Peng, X., see Anand, R., 1046 terfenadine and its metabolites on a delayed rectifier K channel Peoples, R. W., see Li, C., 871 cloned from human heart, 1240 Pepperl, D. J., and Regan, J. W. Selective coupling of a2-adrenergic Rampe, D., Wible, B., Fedida, D., Dage, R. C., and Brown, A. M. receptor subtypes to cyclic AMP-dependent reporter gene expres- Verapamil blocks a rapidly activating delayed rectifier K channel sion in transiently transfected JEG-3 cells, 802 cloned from human heart, 642 Perez, D. M., DeYoung, M. B., and Graham, R M. Coupling of Raynor, K., O’Carroll, A.-M., Kong, H., Yasuda, K., Mahan, L. C., expressed aiB- and alD-adrenergic receptors to multiple signaling Bell, G. I., and Reisine, T. Characterization of cloned somatostatin pathways is both G protein and cell type specific, 784 receptors SSTR4 and SSTR5, 385 Perez, J. J., see Maguire, P. A., 1246 Raynor, K., see Kong, H., 380 Perkins, J. P., see Liao, J.-F., 364 Raynor, K., see Reisine, T., 1016 Persons, S. M., see Rogers, G. A., 633 Redman, R. S., and Silinsky, E. M. A selective adenosine antagonist Pettit, G. R., see Bai, R., 757 (8-cyclopentyl-1,3-dipropylxanthine) eliminates both neuromus- Phillips, C. A., see Liu-Chen, L.-Y., 749 cular depression and the action of exogenous adenosine by an Phillips, E., see McIntyre, P., 346 effect on A, receptors, 835 Phipot, R. M., see Plopper, C. G., 51 Regan, J. W., see Pepperl, D. J., 802 Piattoni, M., see Luetje, C. W., 657 Reily, M. D., see Adams, M. E., 681 Pieters, M. N., see Schouten, D., 486 Reisine, T., Kong, H., Raynor, K., Yano, H., Takeda, J., Yasuda, K., Piqu#{233},J. M., see Goeptar, A. R., 1267 and Bell, G. I. Splice variant of the somatostatin receptor 2 Plassat, J.-L., Amlaiky, N., and Hen, R. Molecular cloning of a mam- subtype, somatostatin receptor 2B, couples to adenylyl cyclase, malian serotonin receptor that activates adenylate cyclase, 229 1016 Plopper, C. G., Weir, A. J., Morin, D., Chang, A., Philpot, R. M., and Reisine, T., see Kong, H., 380 1296 Author Index

Reisine, T., see R.aynor, K., 385 from NG1O8-i5 cells: Increase in opioid agonist efficacy by de- Reisz-Porszasz, S., see Probst, M. R., 511 creased inactivation of G proteins, 731 Rengasamy, A., and Johns, R. A. Regulation of nitric oxide synthase Selley, D. E., see Childers, S. R., 827 by nitric oxide, 124 Shannon, W. M., see Bennett, L. L., Jr., 1258 Renton, K. W., see Armstrong, S. G., 677 Shao, Y., and McCarthy, K. D. Quantitative relationship between a1- Reppert, S. M., see Linden, J., 524 adrenergic receptor density and the receptor-mediated calcium Revah, F., see Quik, M., 678 response in individual astroglial cells, 247 Rhee, J. P., see Wolfe, A. D., 1152 Shaw, P. M., Adesnik, M., Weiss, M. C., and Corcos, L The phenobar- Richelson, E., see Cusack, B., 1036 bital-induced transcriptional activation ofcytochrome P-450 genes Riflund, A. B., see Canga, L., 1142 is blocked by the glucocorticoid- antagonist RU486, Rikihisa, T., see Nakasa, H., 216 775 Rink, T. J., see Beaumont, K., 493 Shealy, Y. F., see Bennett, L. L., Jr., 1258 Riou, J.-F., see Poddevin, B., 767 Sibley, D. R., see Castellano, M. A., 649 Rivkees, S. A., see Linden, J., 524 Siegel, D., Beall, H., Kasai, M., Arai, H., Gibson, N. W., and Ross, D. Robbins, P. D., see Calmels, T. P. G., 1135 pH-dependent inactivation of DT-diaphorase by mitomycin C and Robeva, A. S., see Linden, J., 524 porfiromycin, 1128 Rodriguez, L., see Maguire, P. A., 1246 Sikela, J. M., see Hadingham, K. L., 1211 Rogawski, M. A., see Werkman, T. R., 430 Silinsky, E. M., see Redman, R. S., 835 Rogers, G. A., Kornreich, W. D., Hand, K., and Persons, S. M. Kinetic Silver, R. B., see Canga, L., 1142 and equilibrium characterization ofvesamicol receptor-ligand com- Simasko, S. M., and Yan, S. 3-Isobutyl-1-methylxanthine inhibits plexes with picomolar dissociation constants, 633 sustained calcium current independently of cyclic AMP in neu- Rogowski, R. S., see Werkman, T. R., 430 ronal and endocrine cells, 622 Romero-Avila, M. T., see GarcIa-S#{225}inz, J. A., 589 Simon, E. J., see Gioannini, T. L., 796 Rose, L. M., see Bennett, L. L., Jr., 1258 Simon, R., see Wang, G. K., 667 Rose, P. M., see Webb, M. L., 959 Simpson, M. V., see Keilbaugh, S. A., 702 Ross, D., see Siegel, D., 1128 Skeen, G. A., Twyman, R. E., and White, H. S. The dihydropyridine Rudnick, G., see Schuldiner, S., 1227 nitrendipine modulates N-methyl-D-aspartate receptor channel Ruest, L., see Humerickhouse, R. A., 412 function in mammalian neurons, 443 Russell, M., and Johnson, G. L. G protein amino-terminal a12/a. Skidmore, E., see McIntyre, P., 346 chimeras reveal amino acids important in regulating a, activity, Smit, M. J., see Anderson, R., 605 255 Smolyar, A., and Osman, R. Role of threonine 342 in helix 7 of the 5- hydroxytryptamine type 1D receptor in ligand binding An indirect S mechanism for receptor selectivity, 882 Sadakata, Y., see Yuasa, S., 895 Spreen, R. C., see Lampe, R. A., 451 Saeed, M., see Wolfe, A. D., 1152 Srinivas, R. V., see Gong, Y.-F., 30 Sanders-Buch, E., see Barker, E. L., 725 Steffey, M. E., see Frail, D. E., 1113 Same, Y., see Baumhaker, Y., 461 Stehle, J. H., see Linden, J., 524 Sattelle, D. B., see Blake, A. D., 716 Steiner-Mordoch, S., see Schuldiner, S., 1227 Saunders, P. A., see Fukamauchi, F., 940 Stella, N., see Main, P., 1176 Scaife, K., see Bergsma, D. J., 277 Sterling, K., Weaver, J., Ho, K. L., Xu, L. C., and Bresnick, E. Rat Schilter, B., and Omiecinski, C. J. Regional distribution and expression CYPJAJ negative regulatory element: Biological activity and in- modulation of cytochrome P-450 and epoxide hydrolase mRNAs teraction with a protein from liver and hepatoma cells, 560 in the rat brain, 990 Streicher, R., see Breiner, M., 271 Schmid, E., see Moebius, F. F., 966 Striessnig, J., see Moebius, F. F., 966 Schmidt, J. V., see Dolwick, K. M., 911 Stromstedt, M., Warner, M., Banner, C. D., MacDonald, P. C., and Schmidt, K., Klatt, P., and Mayer, B. Characterization of endothelial Gustafsson, J.-A. Role of brain cytochrome P450 in regulation of amino acid transport systems involved in the actions of nitric oxide the level of anesthetic steroids in the brain, 1077 synthase inhibitors, 615 Strosberg, A. D., see Blin, N., 1094 Schofield, P. R., see Vandenberg, R. J., 198 Su, Y.-M., see Cheng, H.-F., 533 Schols, D., see Jansen, R. W., 1003 Subramaniam, B., see Melvin, L. S., 1008 Scholz, W., see Counillon, L., 1041 Sudan, H. L., see Kerry, C. J., 142 Schouten, D., van der Kooij, M., Muller, J., Pieters, M. N., Bijsterbosch, Suryanarayana, S., and Kobilka, B. K. Amino acid substitutions at M. K., and van Berkel, T. J. C. Development of lipoprotein-like position 312 in the seventh hydrophobic segment of the $2-adre- lipid particles for drug targeting: Neo-high density lipoproteins, nergic receptor modify ligand-binding specificity, ill 486 Sutko, J. L., see Humerickhouse, R. A., 412 Schuldiner, S., Steiner-Mordoch, S., Yelin, R., Wall, S. C., and Rud- Swanson, H. I., see Doiwick, K. M., 911 nick, G. Amphetamine derivatives interact with both plasma mem- Sweitzer, N. M., see de S. Otero, A., 595 brane and secretory vesicle biogenic amine transporters, 1227 T Schwabe,U.,seeLorenzen,A., 115 Schwartz, E. L., see Wadler, S., 1070 Taglialatela, M., Drewe, J. A., and Brown, A. M. Barium blockade of a Schweitzer, B. I., see Fanin, R., 13 clonal potassium channel and its regulation by a critical pore Scofield, M., see Feng, F., 926 residue, 180 Scutari, E., see Zorzato, F., 1192 Takashima, H., see Yuasa, S., 895 Secrist, J. A., III, see Bennett, L. L., Jr., 1258 Takeda, J., see Reisine, T., 1016 Seidenberg, M., see Ellis, J., 583 Takeuchi, K., see Murphy, T. J., 1 Sekiya, K., see Yuasa, S., 895 Tang, L.-H., and Aizenman, E. Long-lasting modification of the N- Selley, D. E., Breivogel, C. S., and Childers, S. R. Modification of G methyl-D-aspartate receptor channel by a voltage-dependent protein-coupled functions by low-pH pretreatment of membranes sulthydryl redox process, 473 Authorlndex 1297

Taylor, H. E., see Linden, J., 524 Weiland, M., see Breiner, M., 271 Taylor, J. E., see Orbuch, M., 841 Weinshank, R. L., see Zgombick, J. M., 575 Taylor, L. P., see Gioannini, T. L., 796 Weir, A. J., see Plopper, C. G., 51 Tegazzin, V., see Zorzato, F., 1192 Weiss, M. C., see Shaw, P. M., 775 Te Koppele, J. M., see Goeptar, A. R., 1267 Werkman, T. H., Gustafson, T. A., Rogowski, R S., Blaustein, M. P., Thanabal, V., see Adams, M. E., 681 and Rogawski, M. A. Tityustoxin-Ka, a structurally novel and Thimmaiah, K. N., see Horton, J. K., 552 highly potent K channel peptide toxin, interacts with the a- Thomas, E. A., Baker, S. A., and Ehlert, F. J. Functional role for the dendrotoxin binding site on the cloned Kvl.2 K channel, 430 M2 muscarmnic receptor in smooth muscle of the guinea pig ileum, Westin, S., Mode, A., Murray, M., Chen, R., and Gustafsson, J.-A. 102 Growth hormone and vitamin A induce P4502C7 mRNA expres- Timmerman, H., see Eriks, J. C., 886 sion in primary rat hepatocytes, 997 Ting, V., see Hamel, E., 242 White, H. S., see Skeen, G. A., 443 Treves, S., see Zorzato, F., 1192 White, M. M., see Filatov, G. N., 237 Trifaro, J. M., see Quik, M., 680 Whiting, P. J., see Hadingham, K. L., 1211 Tim, N. F., see Maguire, P. A., 1246 Whiting, P. J., see Wafford, K. A., 437 Tucker, A. L., see Linden, J., 524 Wible, B., see Rampe, D., 642, 1240 Turlin, B., see Abdel-Razzak, Z., 707 Wilcox, A. S., see Hadingham, K. L., 1211 Twyman, R E., see Skeen, G. A., 443 Wilcox, R. A., Challiss, R. A. J., Liu, C., Potter, B. V. L., and Nahorski, S. R. Inositol-1,3,4,5-tetrakisphosphate induces calcium mobiliza- U tion via the inositol-1,4,5-trisphosphate receptor in SH-SY5Y Ubasawa, M., see Yuasa, S., 895 neuroblastoma cells, 810 Uhler, M. D., see Angelotti, T. P., 1202 Wilken, G. H., see Melvin, L. S., 1008 Upton, C., see Maguire, P. A., 1246 Williams, J. A., see Yang, J., 1158 Usherwood, P. N. R., see Kerry, C. J., 142 Williams, K. Ifenprodil discriminate subtypes of the N-methyl-D- aspartate receptor: Selectivity and mechanisms at recombinant V heteromeric receptors, 851 van Berkel, T. J. C., see Schouten, D., 486 Wilson, A. W., see Hadingham, K. L., 1211 Vandenberg, R. J., Rajendra, S., French, C. R., Barry, P. H., and Wingrove, P. B., see Hadingham, K. L., 1211 Schofield, P. R. The extracellular disulfide loop motif of the Wistrand, P. J., see Maren, T. H., 901 inhibitory glycine receptor does not form the agonsit binding site, Witte, D. G., see Frail, D. E., 1113 198 Witte, D. G., see Wu-Wong, J. R, 285 Van der Goat, H., see Eriks, J. C., 886 Wolfe, A. D., Chiang, P. K., Doctor, B. P., Fryar, N., Rhee, J. P., and van der Kooij, M., see Schouten, D., 486 Saeed, M. Monolconal antibody AE-2 modulates carbamate and Van Rensburg, C. E. J., see Anderson, R., 605 organophosphate inhibition of fetal bovine serum acetyicholines- Vermeulen, N. P. E., see Goeptar, A. R., 1267 terase, 1152 Villar, H. 0., see Maguire, P. A., 1246 Wolff, D. W., see Feng, F., 926 Villemure, J.-G., see Hamel, E., 242 Wong, L. A., and Mayer, M. L. Differential modulation by cyclothiazide Vogt, H., see Lorenzen, A., 115 and concanavalin A of desensitization at native a-amino-3-hy- Volkenandt, M., see Fanin, R., 13 droxy-5-methyl-4-isoxazolepropionic acid- and kainate-preferring Vonvoigtlander, P. F., see Im, H. K., 866 glutamate receptors, 504 Von Zastrow, M., Keith, D. E., Jr., and Evans, C. J. Agonist-induced Wood, S. C., Hill, W. A., and Miller, K. W. Cycloalkanemethanols state of the #{244}-opioidreceptor that discriminates between opioid discriminate between volume- and length-dependent loss of activ- peptides and opiate alkaloids, 166 ity of alkanols at the Torpedo nicotinic acetylcholine receptor, 1219 W Wu, X.-P., and Dolnick, B. J. 5-Fluorouracil alters dihydrofolate re- Wachtel, R. E. Physostigmine block of ion channels activated by ductase pre-mRNA splicing as determined by quantitative polym- acetylcholine in BC3H1 cells, 1051 erase chain reaction, 22 Wadler, S., Mao, X., Bajaj, R., Hallam, S., and Schwartz, E. L. N- Wu-Wong, J. R., Chiou, W., Magnuson, S. R., Witte, D. G., and Lin, (phosphonacetyl)-L-aspartate synergistically enhances the cyto- C. W. Identification and characterization of type A endothelin toxicity of 5-fluorouracil/interferon-a-2a against human colon receptors in MMQ cells, 285 cancer cell lines, 1070 Wu-Wong, J. R., Chiou, W. J., and Opgenorth, T. J. Phosphoramidon Wafford, K. A., Bain, C. J., Whiting, P. J., and Kemp, J. A. Functional modulates the number of endothelin receptors in cultured Swiss comparison of the role of ‘y subunits in recombinant human ‘y- 3T3 fibroblasts, 422 aminobutyric acidJbenzodiazepine receptors, 437 Wynns, G. C., see Maren, T. H., 901 Wafford, K. A., see Hadingham, K. L., 1211 Wyrick, S. D., see Booth, R. G., 1232 Wall, S. C., see Schuldiner, S., 1227 Waltham, M., see Fanin, R., 13 x Wang, G. K., Simon, R., Bell, D., Mok, W. M., and Wang, S.-Y. Xu, L. C., see Sterling, K., 560 Structural determinants of quarternary ammonium blockers for batrachotoxin-modified Na channels, 667 Y Wang, S.-Y., see Wang, G. K., 667 Yan, S., see Simasko, S. M., 622 Warner, M., see Str#{246}mstedt, M., 1077 Yang, J., Logsdon, C. D., Johansen, T. E., and Williams, J. A. Human Watkins, S. C., see Calmels, T. P. G., 1135 m3 muscarinic acetylcholine receptor carboxyl-terminal threonine Weaver, J., see Sterling, K., 560 residues are required for agonist-induced receptor down-regulation, Webb, M., see McIntyre, P., 346 1158 Webb, M. L., Liu, E. C. K., Monshizadegan, H., Chao, C.-C., Lynch, Yano, H., see Reisine, T., 1016 J., Fisher, S. M., and Rose, P. M. Expression ofendothelin receptor Yao, Y. H., see Gioannini, T. L., 796 subtypes in rabbit saphenous vein, 959 Yasuda, K., see Kong, H., 380 Weight, F. F., see Li, C., 871 Yasuda, K., see Raynor, K., 385 1298 Author Index

Yasuda, K., see Reisine, T., 1016 Weinshank, R. L., and Branchek, T. A. Dual coupling ofthe cloned Yeh, J.-R., see Cheng, H-F., 533 human 5-hydroxytryptaminelD[cflOja[cfl] and 5- Yelin, R., see Schuldiner, S., 1227 hydroxytryptamineiD[cfiO]fl[cfl] receptors stably expressed in mu- Young, A. A., see Beaumont, K., 493 rine fibroblasts: Inhibition of adenylate cyclase and elevation of Young, J., see Lampe, R. A., 451 intracellular calcium concentrations via pertussis toxin-senstivie Yu, F., see Bachur, N. R., 1064 G protein(s), 575 Yu, H. J., Ma, H., and Green, R. D. Calcium entry via L-type calcium channels acts as a negative regulator of adenylyl cyclase activity Zhong, H., and Minneman, K. P. Close reciprocal regulation of and and cyclic AMP levels in cardiac myocytes, 689 32-adrenergic receptors by dexamethasone in C6 glioma cells: Ef- Yu, L., see Chen, Y., 8 fects on catecholamine responsiveness, 1085 Yuasa, S., Sadakata, Y., Takashima, H., Sekiya, K., Inouye, N., Uba- Zhu, Y.-S., Brodsky, M., Franklin, S. 0., Huang, T., and Inturrisi, C. sawa, M., and Baba, M. Selective and synergistic inhibition of E. Metrazole induces the sequential activation of c-fos, proenke- human immunodeficiency virus type 1 reverse transcriptase by a phalin, and tyrosine hydroxylase gene expression in the rat adre- non-nucleoside inhibitor, MKC-442, 895 nal: Modulation by glucocorticoid and adrenocorticotropic hor- mone, 328 Z Zorzato, F., Scutari, E., Tegazzin, V., Clementi, E., and Treves, S. Zaidi, J., see Cusack, B., 1036 Chlorocresol: An activator of ryanodine receptor-mediated Ca2 Zgombick, J. M., Borden, L. A., Cochran, T. L., Kucharewicz, S. A., release, 1192

4S, Statsm#{149}ntof Ownership, Management and - Carculatson (R.q,,...dby39U.SC. 36851

MOI1CUIMI PI!SRMACOI OCY OIO 2618191 5 1 101L....

?.nth1y 12 $105.00

, c_.-_. *... .. C.--- .‘ C.,. C. $. Zr.. C

428 East Pwston Street Balti.ore,?(D 21202-3993 *.*.., ,‘ . ,..-.-,-. ., G.._ S...ss 0”... .‘ ,. P,....

428 kast Preston Stzeet. Ba1tAre,KD 21202-3993

, ,-. ,-*, .- c_,...,. .,...‘ - ITh. . lVU OT*. , . c_

Williams 6 WIlkins, 428 East Preston Stret, Daltimore,MD 21202-3993

Dr. 2. Kendall Harden, CD 67368, Lpartnt of Pharaacology, University of North Carol,na School of 1#dicine. Chaoel Hill. NC 27599-7368

, o__., 8- 0#{149}p. , o, o, . ‘0” 6..O. .. - . -.--“,.- .. - -. - 4.-’ ,, I.-. ‘# -

, NO.. c_ M., AJoorlcan 5ocAct9 for Pharmc-o1ogy rio Kay Croker and rintaI Therapeutics Executive Director 965fl Rrki I Jo Pj.ke Jeth.sda ND 20#{176}14

S C-.-’ . O-.., .o., M. 0 *..., . S0. 0,0.

ii , N [ c..,,. M..,

O,o. ‘0 C0.. D. ‘0. t00.,0 0 O.. , .,... 4 0..., 2 .-o.. “...ar 1 . .,. ..0 0,

0 0....,.0. Ao..0. C.,..., S-i0’... ,. - .,-.- ., p,.(.,_., 3 M0s p0*. N,.,, . ‘., 0.,.

* ?,.00. C* 0.. P..* 2232 2150

191 189 , ,,.. .0,

,,--“.- -‘--.4, 1420 1383

1651 1572 0 C00.0. 87 98

, ?.0 0....0.0’. $.4C0O 1698 1670

-_.0,(. -.. *0 534 400 2 fl.,..- ‘..-. 0.. scwo: 901(6 2232 2150 0 0.41 0

::::,.th:= ard c. PUBLISHER Ps....3526.o...., Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics Publications of the American Society for Pharmacology and Experimental Therapeutics, Inc.

The Journal of Pharmacology and Experimental Molecular Pharmacology Therapeutics Editor: 1. Kendall Harden, Ph.D. The papers published in Molecular Pharmacology Editor: John A. Harvey, Ph.D. are on the cutting edge of research on drug action and selective JPET is respected the world over as one of the toxicity at the molecular level. Original applications of leading research journals in the field of pharmacology. You’ll biochemistry, biophysics, genetics, and molecular biology are find broad coverage of all aspects of the interactions of juxtaposed with innovative pharmacologic research to elucidate chemicals with biological systems, including autonomic, basic problems in pharmacology and toxicology, including such behavioral, cardiovascular, cellular, clinical, developmental, areas as molecular mechanisms involved in drug receptor- gastrointestinal, immuno-, neuro-, pulmonary, and renal effector coupling, xenobiotic metabolism, and antibiotic and pharmacology, as well as analgesics, drug abuse, metabolism anticancer drug action. Mont hlv and disposition, chemotherapy, and toxicology. Monthly.

Drug Metabolism and Disposition: the biological fate of chemicals Editor: Vincent G. Zannoni, Ph.D. Drug Metabolism and Disposition publishes in vitro and in vivo experimental results that bring you significant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants and preservatives. The areas covered are: pharmacokinetics, pharmacodynamics and mechanisms, genetic, nutritional, or hormonal factors affecting the biological fate of chemicals, toxicological consequences of xenobiotic metabolism. Bimonthly.

Pharmacological Reviews Editor: Robert E. Stitzel, Ph.D. Pharmacological Reviews is a showcase for important review articles in your field, featuring longer papers on topics of high current interest. The areas covered in review papers have included biochemical and cellular pharmacology, drug metabolism and disposition, renal pharmacology, neuropharmacology, behavioral pharmacology, clinical pharmacology, and toxicology. No library serving the pharmacologic community should be without a subscription. Quarterly.

:- Please enter my subscription to the following: Payment Options: E:JCheck enclosed (payable to I The Journa’ of Pharmacology and Experimental I Therapeutics (monthly) Williams & Wilkins) I Individual $190/year l Institutional $340/year (Add $65/year for c:Bill me EJ American Express I subscriptions outside the U.S.; in Canada, also add 7% GST.) JMasterCard JVISA Card#______l New Subscription l Renewal Exp. date Signature or P.O. # ______ Subscribe for: 3 years 1 2 years l I year

Drug Metabolism and Disposition (bimonthly) Name Individual $85/year C1 Institutional $140/year (Add $20/year for subscriptions Address outside the U.S.; in Canada, also add 7% GST.) City/State/Zip :: New Subscription J Renewal I 6 Please indicate institution/status Subscribe for: r:i3 years J 2 years ] 1 year I

I Molecular Pharmacology (monthly) MD and PA subscribers must add state sales tax. 5ubscriptions outside the U.S. must he prepaid I l Individual $105/year J Institutional $230/year (Add $30/year for in U.S. dollars. In Japan. contact lgaku.shoin. MYW. Ltd. (03) 565954(X). Rates valid through I subscriptions outside the U.S.; in Canada, also add 7% GST.) October31. 994. J New Subscription 5 Renewal Subscribe for: c:i 3 years 1 2 years (1 1 year Return coupon to: I Williams & Wilkins I I Pharmacological Reviews (quarterly) A WAVERLY COMPANY ri Individual $60/year I Institutional $107/year J In-training $45/year (Add $15/year for subscriptions outside the U.S.; in Canada. also add 7% GST.) P.O. Box 23291, Baltimore, MD 2 1203-9990 I New Subscription J Renewal ( For credit card orders, call TOLL FREE: I Subscribe for: r::3 years 2 years i I year ‘ei 1-800-638-6423 in the U.S. or Canada. L_ J4075S zP1j DRUG M OLISM AND DISPOSITION The Biolooicalrate at Chemicals

Editor: Vincent G. Zannoni, PhD, University of Michigan, Ann Arbor, Michigan

DRUG METABOLISM AND DISPOSITION publishes in litr() and /n l’ll’() experimental results that bring readers signifIcant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants, and preser- vativcs. All papers are refereed to ensure a high standard of publication. The areas covered are: e pharmacokinetics e pliarmacodvnaniics e genetic. nutritional, and hormonal factors affecting the biological tate of chemicals e toxicological consequences of xenohiotic metabolisni

This journal should he a standard reference in all pharmacology and toxicology departments. It is also a valuable resource for all niedicinal chemists involved in designing drugs and all hiochemists involved with drug metabolism.

Bimonthly

Ad

,

Avoid future rate increases and ensure uninterrupted service - enter Payment options: YOUr nisiltiVeaf subscription today! E Check enclosed 0 Bill me VISA E MasterCard American Express Drug Metabolism and Disposition (bimonthly) ______E Individual: c; yr E Institutions: S l-eOvr card ( Please a/t’1 S20.O() outside the ( in Catiada, (i/So add % GST) ______E New Subscription E Renewal E 3 %TS 2 yr E 1 yr signature P.O.

MD and PA subscribers must add state sales tax. Schscrtption from outside the US and Canada must he prepaid. in US dolla,:s ott/v. In Japan. contact Igaku- Shoin MYW Ltd. (03) 5689-5400. Rates valid for orders recer.ed before October ______31. 1004.

namt. Plcisc alloss S ssccks for deltscr of your first issue. Surlacc mail dcliscrv to countries outside the US niay take up to 16 ssccks. Airmail rates available upon address request. Discounts as ii1ahIe to menher. on all .ASPET publications. SA\E I1V a hen rd rio tss ‘A\ E I sh ii r I rinc thu. ‘A\ E It ssh is rd rim.. ill 1 ur

clt\ ‘t1tt up .. - \Villiams & \Vilkins Broadway House P.O. Box 23291 2-6 Futham Broadway I A \VAVERLY COMPANY Baltimore. Maryland 21203-9990 London SW6 1AA England I DMD 55020 Printed in USA J40205 ZDMD Previous Editors 1965 Avram Goldstein, Editor. Stanford University. 1968 Paul Talalay, Editor; Donald S. Coffey, Associate Editor. Johns Hopkins University. 1971 Steven E. Mayer, Editor, Palmer W. Taylor, Associate Editor. University of California at San Diego. 1975 George I. Drummond, Editor; H. Joseph Goren, Associate Editor. University of Calgary. 1978 Norman Kirschner, Editor; Theodore A. Slotkin, Associate Editor. Duke University. 1983 Joel G. Hardman, Editor; Lee Limbird, F. Peter Guengerich, Associate Editors. Vanderbilt University. 1986 William A. Catterall, Editor; Joseph A. Beavo, Mont A. Juchau, Neil M. Nathanson, Daniel A. Storm, Frank F. Vincenzi, Associate Editors. University of Washington, Seattle.

B. 1) L. C

Williams&Wil1nsQuick Copies. RATES, PER ARTICLE Fai phone. or tnail)vur citation to: 1-5 pages $10 Williams & Wilkins Tellus today.Read ittomorrow. Quick Copies 6-10 pages $12 428 East Preston Street #{176}can get copies ofany article published in all Williams Y 11-15 pages $15 Baltimore, MD 21202-3993 & Wilkins journals. It’s fast - because we’re the pri- 16-20 pages $18 Call 1-800-354-9685 (toll free) Fax 1-410-528-4312 mary source, we can fax itto you within 24 hours of when 21-25 pages $20 we receive it. It costs less - there are no copyright fees 26+ pages $25 and the cost of faxing is included in the price. It’s ( Williams &Wilkins ($20, Federal Express) 1(u’A WAVERI.Y COMP\\ affordable - look at the table to the right. DDSAD 54525